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Review Articles

The Controversy Over Cocaine Use and Beta-Blockade
Continues to Brew
Ankitkumar K. Patel, MD, MPH
Cocaine Abuse Epidemiology

Cocaine is the second most commonly used illicit drug and
the most frequent cause of drug-related deaths in the United
States.1 Approximately 24 million people in the United States
have used cocaine at least once, and five million abuse cocaine
on a regular basis.2 Its use is associated with acute and chronic
complications affecting many organ systems, the most common
being the cardiovascular system.3

Cocaine Pharmacology

Cocaine acts as a powerful sympathomimetic agent. Cocaine has
two main mechanisms of action. Its first mechanism involves the
inhibition of cellular sodium ion transport through blockade of
fast sodium ion channels, resulting in membrane stabilization
and a local anesthetic effect. In the myocardium, this effect
is similar to that produced by class 1 antiarrhythmic agents.4
The second mechanism is a marked increase in catecholamine
levels at the synapse by blockage of presynaptic reuptake of
epinephrine, norepinephrine, and dopamine. The result is
elevated levels of these neurotransmitters at the postsynaptic
receptors.5
Stimulation of α-adrenergic receptors leads to coronary
vasoconstriction.6 Cocaine not only causes spasm of the large
coronary arteries but is toxic to cardiac muscle. Excessive βadrenergic stimulation from cocaine causes calcium overload,
which directly leads to cardiac myocyte toxicity.7 Stimulation of
β-adrenergic receptors has positive chronotropic and inotropic
effects on the myocardium and thus increases myocardial
oxygen demand. Due to increased norepinephrine activity on αand β-adrenergic receptors, cocaine produces a dose-dependent
increase in heart rate and blood pressure, which usually remains
within physiological levels in recreational use. 8 In human
volunteers, intranasal cocaine produces a significant increase
in blood pressure, heart rate, coronary vascular resistance, and
myocardial oxygen consumption compared to intranasal saline
administration.9
Lastly, cocaine can precipitate coronary thrombosis.10 It increases
platelet aggregation through elevated levels of thromboxane A2
and epinephrine.11

Cocaine and Chest Pain

Chest pain is the most common symptom reported by cocaine
users.12 Data suggests that most patients with chest pain are
not questioned about cocaine use and if they are, the answer
is often not documented.13 Fifty-seven percent of cocaine users
complaining of chest pain are admitted to the hospital.14
Acute coronary events and myocardial infarction can occur
within minutes to days after cocaine administration.15 Cocaineinduced myocardial infarction is difficult to diagnose since
the most common ECG finding is early repolarization and left



ventricular hypertrophy.16 The anterior wall is involved in 77%
of cases of cocaine-induced myocardial infarction.17 A small case
study found users of cocaine have a transient 24-fold increase in
risk of myocardial infarction in the first hour after use which
decreases rapidly thereafter.18

Management of Cocaine-induced Chest Pain

Patients who have myocardial ischemia secondary to cocaine
use are medically treated differently from patients who have
myocardial ischemia unrelated to cocaine. Current recommendations for the treatment of cocaine-induced myocardial
ischemia include use of benzodiazepines, cautious use of
thrombolytics, and avoidance of beta-blockers.19

Controversy over β-blocker usage

During myocardial infarctions, β-blockers prevent the excessive
catecholamine stimulation that leads to myocardial necrosis or
stunning.20 The benefit of β-blockers in myocardial infarction is
the prevention of reinfarction and ventricular fibrillation.21
In 1976, Rappolt et al recommended the use of intravenous
propranolol in the management of cocaine intoxication based
on their observations of over 50 cases of successful treatment.22
As a result of these findings, propranolol became the preferred
treatment for cocaine-induced hypertension until 1985 when
Ramoska and Sacchetti suggested that propranolol should be
used with caution due to its potential for causing paradoxical
hypertension via “unopposed alpha stimulation.”23 By blocking
the β-adrenergic receptors, available neurotransmitters
predominantly bind α-adrenergic receptors on smooth muscle
and cause vasoconstriction of blood vessels, thereby elevating
blood pressure.
However, a recent retrospective study of 363 consecutive
telemetry and ICU patients who were admitted to a municipal
hospital for chest pain and had positive urine toxicology results
for cocaine demonstrated a decrease, rather than an increase,
in the risk of death and myocardial infarction with β-blocker
administration. The incidence of myocardial infarction in the
group of patients treated with β-blockers was significantly lower
than the group without therapy (6.1% vs. 26%; 95% CI: 10.330%).24 In a corresponding editorial, Freeman and Feldman
question the premise that cocaine chest pain is due to coronary
artery spasm.25 Firstly, cardiac catheterization in initial studies
of patients with cocaine-induced chest pain was conducted in
a delayed fashion, so that spontaneous thrombolysis could not
be excluded.26 Secondly, reversible coronary perfusion defects,
consistent with coronary vasospasm, are rarely demonstrated in
acute myocardial perfusion imaging.27
In a small clinical study, labetalol was shown to reverse the
cocaine-induced rise in mean arterial pressure, but does not
alleviate cocaine-induced coronary vasoconstriction.28 However,

to date no clinical trials have been conducted on the initial
management of cocaine-associated ischemia or infarction. 29
Specifically, a study to assess the risk-to-benefit ratio of βblocker usage in patients who complain of chest pain and test
positive for cocaine would provide much needed clarification.
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Palmarplantar Keratodermas
Melissa Gitman, MD, CM

Case Presentation

A 44 year old African American female with a history of seizure
disorder and cirrhosis secondary to alcohol abuse was brought
to the emergency department (ED) after a witnessed generalized
tonic-clonic seizure on the street. While the patient was in the ED,
she was observed to have 500cc of bright red hemetemesis and
promptly transferred to the intensive care unit with successful
stabilization of an upper GI bleed. It was not until transfer back
to the telemetry that she was noted to have a shiny, scaly lesions
on her hands and feet bilaterally (Figures 1 and 2).

Figure 3. Adapted from Patel et al
Figure 1.

Figure 2.

Discussion

When evaluating a patient with PPK, the first step is to perform
a detailed history and physical, including a complete skin exam.
Patel et al proposed an algorithm to evaluate patients thought to
have acquired PPK of unknown etiology (Figure 3).1



Palmoplantar keratodermas (PPK) is comprised of a
heterogeneous group of conditions that are characterized by
hyperkeratosis of the palms and soles.1 These conditions can be
classified in several different fashions. First of all, a distinction
between the hereditary and acquired forms must be determined.
Furthermore the hereditary forms can be further subdivided
depending on the extent of involvement of the epidermis
(focal, diffuse or punctuate), the location of the lesions, the
mode of inheritance, the age of onset and the presence of comorbid conditions. Moreover, with advancements in molecular
genetics, these conditions can also be classified by the type of
gene dysfunction that occurs, including mutations in the genes
responsible for synthesis of structural proteins, cornified envelope,
cohesion, connexins and trans-membrane signal transducers.2
While PPK may be found in the absence of other conditions, it
is often found as part of a disease complex, such as skin findings
associated with deafness, corneal dystrophy, cardiac structural
abnormalities, gingival hyperplasia and esophageal malignancy.
In the hereditary form, a genetics consult should be obtained in
order to further evaluate the specific type of PPK present.2
Similarly the acquired form of the condition can be further
subdivided into categories based on their etiology. Patel et
al proposed the acquired PPK’s be subdivided as follows:

keratoderma climactericum, drug related, malnutrition
associated, chemically induced, systemic disease related,
malignancy associated, dermatoses related, infectious etiology
and idiopathic.1 Keratoderma climactericum is typically found
in menopausal women, frequently with co-existent obesity or
hypertension. The condition begins with involvement of the
plantar aspect of the feet, where the patient develops erythema,
hyperkeratosis and fissuring, leading to difficulty ambulating.
Palmar involvement occurs later in the disease course. Chemical
associated PPK has been described with a history of exposure to
arsenic and chloracnegens. Symptoms generally resolve a few
months after removal of the exposure, however, in some cases,
symptoms have persisted for several years. Severe malnutrition
in concentration camp inmates has also been reported to be
associated with acquired PPK. A deficiency in both protein and
vitamins led to the condition which improved with vitamin
replacement. Multiple medications, including glucan, lithium,
venlafaxine, verapamil, quinacrine and certain chemotherapy
agents, have all had case reports in the literature associating their
use with PPK. Generally, the diagnosis is made in retrospect
with resolution of the symptoms upon discontinuation of the
offending agent. Several dermatologic conditions, including

psoriasis, lichen planus and eczema have all been reported to
cause a reactive form of PPK. Certain infections, including
HIV, syphilis, scabies and TB have all been reported to cause
hyperkeratosis. PPK is also considered to be a paraneoplastic
marker for malignancies of the esophagus, lung, breast, blood,
bladder, and GI tract.
Tripe palm is a specific finding which refers to form of palmar
keratoderma with a velvet-like texture and exaggeration of the
lines of the palm and fingers. Greater than 90% of patients
with this finding have an underlying malignancy. Of course,
idiopathic acquired PPK is a diagnosis of exclusion after all
other etiologies have been eliminated.1
Treatment of PPK usually involves treatment of the underlying
etiology. If no causative process is identified then a conservative
approach is undertaken using topical therapies to lessen the
dermatologic symptoms.1
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Syncope

Melissa Gitman, MD, CM

Case Presentation

A 45 year old white female rising from her seat to give a lecture
at the Philadelphia Convention Center suddenly collapsed and
lost consciousness. An automated external defibrillator device,
on hand at the conference, demonstrated her rhythm to be in
ventricular fibrillation. She was subsequently defibrillated
and intubated in the field yet was unresponsive on arrival.
Her husband related that his wife’s past medical history was
significant for hypothyroidism and a questionable diagnosis of
lupus. Her medications included levothyroxine and Pycnogenal,
a popular herbal supplement. She had no known drug allergies.
The patient had no known tobacco, alcohol, or illicit drug abuse
and works as an employee of federal government.
Hemodynamic vitals were stable. Cardiac exam revealed a
regularly regular rhythm with normal heart sounds, and no
jugular venous distention. Lungs were clear to auscultation and
the abdomen was completely benign. The patient was warm with
good distal pulses bilaterally and withdrew to pain and noxious
stimuli though a complete neurologic exam was difficult to
obtain at the time of admission.
Laboratories were significant for a potassium of 2.7 mEq/mL. The
remaining electrolytes were normal. Her complete blood count,
urine drug screen, and cardiac enzymes were within normal
limits. Head CT demonstrated no intracranial abnormalities. An
echocardiogram demonstrated normal left and right ventricular
systolic size and function, though a small pericardial effusion was
noted. Her initial EKG demonstrated a prolonged QT interval
with a corrected QT value (QTc) of 510 ms.

Discussion

The differential diagnosis of syncope in the younger adult differs
slightly from that of the more classic presentation of syncope in
the older adult (Table 1).1 However, in both age groups one must
consider both cardiac and non-cardiac causes. Arrhythmias and
structural abnormalities figure prominently, though in these
patients greater consideration must be given to congenital
anomalies. In this particular case, the differential is narrower
still, as the patient suffered sudden cardiac death (SCD). The
differential of this condition includes: Congenital and Acquired
Long QT syndrome, Wolff-Parkinson-White syndrome,
idiopathic ventricular fibrillation, and coronary artery spasm.1
In light of the patient’s EKG findings, the diagnosis of prolonged
QT syndrome was given and what follows is a discussion of this
condition.

Long QT syndromes (LQTS)

Prolonged QT syndrome is defined as QT c > 440 ms in men
or >460 ms in women.2 This is based upon the QT interval as
measured in lead II. The Bazett correction formula (QTc = QT x
RR1/2) is frequently used to calculate the corrected QT interval.
In acquired LQTS, an increase of greater than 25% from baseline



is considered to be significant.2 The condition is thought to
be caused by lengthening of the repolarization phase of the
ventricular action potential. It is a disease of ion channels due
to mutation of genes encoding for transmembrane Na+ and K+
ion channel proteins. LQTS is hypothesized to be due to either
a slowing of inward depolarizing Na+ currents or slowing of
outward repolarizing K+ currents.2
Two forms of the condition have been described, congenital
LQTS and an acquired form. Congenital LQTS is an inherited
disease which presents with sudden cardiac death in patients
with structurally normal hearts.3 It is an autosomal recessive
condition and mutations in 7 genes have been identified
accounting for ~60% of families affected. The precise incidence
of LQTS is unknown, although it is estimated to be 1 in 7,000
to 10,000 in the US.2 It is more prevalent in Utah and Finland.
LQTS is thought to cause 3000-4000 sudden deaths in children
and young adults in the USA.3 Untreated, it is a lethal condition
with a 10 year mortality rate being between 50-70%.3

Risk factors for acquired QT prolongation

Several factors related to medication use lead to QT prolongation.
This includes: the use of medications that prolong the QT interval
(Table 2), concurrent use of medications that prolong the QT
interval; the use of medications that slow drug metabolism due
to inhibition of hepatic cytochrome P450 enzymatic system;
impaired hepatic or renal function; dose and or concentration
dependent response; the rate of medication infusion; and
certain recreational drugs such as cocaine, amphetamines,
and methadone.4 It is believed that low potassium levels, low
magnesium levels and other electrolyte disorders can causes
acquired form of the condition.4
Cardiac risk factors for QT prolongations include structural
heart disease and recent conversion from atrial fibrillation. While
bradyarrhythmias can lead to QT prolongation this is usually
related to taking antiarrhythmic medications and therefore is not
necessarily an independent risk factor. Neurologic risk factors
include stroke and subarachnoid hemorrhage. HIV infection
can lead to QT prolongation due to a number of factors such
as myocarditis, subclinical cardiomyopathy, and autonomic
neuropathy. Eating disorders can also lead to electrolyte disorders
leading to conduction disturbances. Connective tissue disorders
with anti-RO/SSA antibodies are additional risk factors for QT
prolongation. Finally, the condition is more common in females
compared to males, an association thought to be an estrogen
mediated effect.4
There is some controversy as to whether acquired LQTS is, in
fact, its own distinct entity. Some schools of thought maintain
that there is only a congenital form of LQTS that remains
undetected until it is unmasked by one of the above mentioned
factors. Of note, in patients with drug induced LQTS almost

all have blockade of the Ikr current which is mediated by the
K+ channel encoded by the HERG gene. The same channel is
involved in LQT2, raising the question of whether these patients
have a genetic predisposition to developing the condition.4
Additionally, one study of 817 family members of patients with
documented congenital LQTS by genetic testing yielded an
average penetrance of 60%.4

Work-Up

As with any other condition, the first step in diagnosis is a
thorough history. Approximately 60% of patients with familial
LQT are symptomatic.3 Palpitations are an uncommon finding
because torsades usually are too fast to support any circulation.
Rather patients might give a personal history of syncope or
seizure-like activity especially with activity or severe stress. Each
of the congenital forms possess their respective triggers. For
example in LQT1, cardiac events are frequently associated with
vigorous physical activity especially with diving and swimming.
In LQT2 the patients are sensitive to sudden arousal such as
sudden loud noises. On the other hand, LQT3 patients frequently
experience events during rest or sleep. Asymptomatic patients
come to medical attention after an affected family member or a
prolonged QTc is identified on an ECG obtained for some other
reason.3 Data from the International Registry demonstrated
that by age 40, cardiac events (syncope, SCD, or cardiac arrest)
occurred in 17% of family members overall, and in 26% of
those with a prolonged QT interval.5 First-degree relatives had a
higher incidence of cardiac events by age 40 than second-degree
relatives (26% vs 10%). Additionally, a detailed family history
should be obtained to determine if there are any relatives with a
history of sudden death in infancy or young adulthood during
nocturnal, startle, or athletic activity, near-drowning, or any
family history of SIDS.3 In general, the physical exam does not
provide any specific findings.
Of course, an EKG must be obtained in all patients suspected of having the
condition to assess the QT interval. However, data from the International
Registry for LQTS showed that 5% of 1345 family members presented
with cardiac arrest had a normal QTc. In fact, only 70% of gene carriers
have a prolonged QTc5. Some additional ECG findings in this condition
include notched T waves noted during the recovery phase of exercise
testing suggestive of LQTS and T-wave alternans noted during physical
or emotional stress. Ten typical ST-T patterns have been described in
LQTS. The QT dispersion in a 12-lead ECG (QTc max-QTc min) should
also be noted.5 An EKG obtained during an acute event demonstrates
either Torsades des Pointes or ventricular fibrillation with a short-longshort sequence being the hallmark of LQTS. Repeat EKG testing is
necessary in patients with a high clinical suspicion as normal QTc and
normal T wave morphology do not exclude the disease. It can be helpful
to obtain an ECG from immediate family members for comparison.
Additional testing modalities have been examined for diagnostic
purposes. Exercise stress testing can be used to detect the
condition in patients with borderline length QT intervals, as

an ECG obtained post-exertion may show QT prolongation.
However, pharmacologic provocation studies have not been
well studied. Holter monitoring can also be utilized to detect
intermittent QT prolongation, bradyarrhythmia, T wave
alternans, and notched T-waves. EP testing though, is not
diagnostic of the condition. Finally, genetic screening may be
useful in families with known genotype, however it is mainly
used for research purposes.

Complications

The main concern in this patient population is the development
of Torsades de Pointes and ventricular fibrillation. Sudden death
is the only event in 30-40% of patients. Untreated symptomatic
patients with LQTS have a greater than 20% mortality rate in the
first year after an initial syncopal episode.3

Management

In the short term, immediate cardioversion to terminate
arrhythmias is frequently required. This is usually followed
by withdrawal of offending agents if present and correction of
electrolyte abnormalities. Magnesium is effective in suppression
of short term recurrences of torsades irrespective of baseline
magnesium levels. A single bolus of 2 g of magnesium should
be given over 2-3 minutes followed by an intravenous infusion
of 2-4mg/min. A second 2 g bolus should be administered
either 15 minutes later or immediately if torsades recur while
the magnesium is being infused.6 Potassium is used as an
adjunct to intravenous magnesium. In pts with LQT2 some
evidence to suggest maintaining high normal levels (4.5-5.0)
of potassium may be beneficial.6 However there is no evidence
of any effect on preventing or reversing torsades. Temporary
transvenous cardiac pacing to a rate of 100 beats per minute
can be used in patients who fail magnesium therapy. This
has been demonstrated to be beneficial regardless of baseline
heart rate. Isoproterenol can also be used as it controls short
term recurrence of torsades by increasing heart rate. An initial
dose of 2 mcg/kg/min is given and then titrated to heart rate
of 100 bpm. Of note, isoproterenol cannot be used in pts with
congenital LQT because of adrenergic stimulating effects.6
In terms of long term management, it is clearly agreed upon
that all symptomatic patients should be treated. Conversely, it
is unclear as to whether other groups of asymptomatic patients
should be treated. Prophylactic treatment is recommended in
all intermediate and high risk patients. In patients with LQT1
this means male and female patients with QTc >500ms. In
LQT2 this includes male patients with a QTc of > 500ms and
all females. All patients with LQT3 should be treated prophylactically. Asymptomatic patients who should be treated include
all patients with congenital deafness, neonates and infants,
affected siblings of children who have died suddenly, patients
with documented T-wave alternans and patients with very long
QT (>600ms).



Table 1. Differential Diagnosis of Syncope in a Younger Adult
Cardiac syncope

Noncardiac syncope

Arrhythmia

Vasovagal response
to pain

Ventricular arrhythmias
Ventricular tachycardia
Torsade de pointes
Supraventricular tachyarrhythmias
Bradyarrhythmias
Sinus bradycardia

Situational syncope
(Micturition, defecation,
tussive, and carotid sinus
syncope)
Autonomic dysfunction

High-grade atrioventricular blocks
Pacemaker malfunction
Low flow states

Neurovascular causes

Advanced cardiomyopathy
Congestive heart failure

Volume depletion –
dehydration, hemorrhage

Valvular insufficiency

Addison’s disease

Cardiac outflow obstruction

Psychiatric disease incl
cardiac manifestations of
anorexia nervosa

Aortic stenosis
Hypertrophic obstructive
cardiomyopathy

Hypoglycemia

Mitral stenosis
Pulmonary stenosis
Pulmonary embolus
Left atrial myxoma
Pericardial tamponade
Acute MI
Aortic dissection
Primary pulmonary hypertension

Table 2. Drugs That Prolong the QTc Interval
CNS

ziprasadone,
thioridazine,
risperidone

Antibiotics

clarithromycin,
ketoconazole,
fluconazole,
moxifloxacin

approx 25% of treated patients.5 Maximal beta blockade should
be implemented to a target of <130 bpm at maximal heart rate.
There have been no studies comparing different agents but
agents with longer half-life are preferable secondary to noncompliance. Commonly used agents include propanolol at a
dose of 2-3 mg/kg and nadolol dosed at 1 mg/kg.5 Pacemakers
are used as an adjuvant to beta blockers in patients with
bradycardia or AV node blockade.
Left cardiac sympathetic denervation has been attempted in
patients who failed beta blocker therapy. The largest study to
date looked at 123 patients and demonstrated a decrease in
the number of cardiac events from 99% to 45%, with a 5 year
survival rate of 94%.7 AICD devices are first line therapy for
any patient surviving a sudden cardiac arrest. They are also
commonly used in patients who fail all other therapies. However
AICD devices, especially if they misfire, can produce emotional
distress triggering arrhythmias and shocks, therefore one should
continue adjuvant therapy with beta blockers. Finally the long
term efficacy of ablation remains unknown.
Current therapies under investigation include: Na+ channel
blockers such as mexiletine, flecainide, lidocaine, pentisomide,
and phenytoin; K+ channel activators such as nicorandil, pinacidil,
and cromakalim; alpha-adrenergic receptor blockers; calcium
channel blockers; atropine; and protein kinase inhibitors.7
Monitoring of these patients includes a baseline EKG with followup EKG’s on treatment with QT prolonging medication. Also,
patient education is paramount. Patients need to be instructed
to report any symptoms including palpitations, pre-syncope or
syncope. Patients and physicians must be cautious with any
new medications. Patients should also report clinical changes
and side effects that may signal hypokalemia such as gastroenteritis. It is important for these patients to avoid activities that
can act as trigger events. Finally, screening of family members
is necessary to pick up subclinical cases.
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Beta-blockers are the first line therapy in symptomatic patients.
Approximately 75% of cardiac events are precipitated by
adrenergic stimuli. As a result beta blockers reduce mortality
from 71% to 6%, however syncope and other events recur in
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Clopidogrel-Associated Thrombotic Thrombocytopenic
Purpura: A Case Report and Brief Review
Benjamin C. Creelan, MD
Introduction

revealed abnormal hemoglobin
(5.6 g/dL), platelets (8.0 x 109/
In 1991, Page and colleagues
l), lactate dehydrogenase (2847
published a report of four
IU/L), indirect bilirubin (3.0
cases of thrombotic thrombomg/dL), serum creatinine (1.6
cytopenic purpura (TTP)
mg/dL), and haptoglobin (< 0.6
attributed to treatment with
µmol/L). Urinalysis revealed 66
the platelet ADP receptor
red cells per high power field.
antagonist, ticlodipine.1 Since
Severe schistocytosis was noted
then, ticlodipine has been
on peripheral smear (Figure
established as an immune1). Direct antiglobulin testing
mediated cause of TTP with
was negative and fibrinogen
an incidence of approximately
levels were normal (483 mg/
0.02-0.06%. 2, 3 Due to its
dL). Serum carcinoembryonic
unfavorable side-effect profile,
the use of ticlodipine has been Figure 1. Chemical structure of ticlopidine (Ticlid®) compared to antigen to detect recurrence of
colorectal cancer was negative,
mostly discontinued in the clopidogrel (Plavix®) 17
and computed tomography (CT)
United States and replaced
scan of the abdomen did not show local recurrence or metastases.
by clopidogrel. Both agents are thienopyridine-derivatives
Blood cultures did not grow organisms. Transthoracic echocarwhich differ only by a carboxymethyl moiety. In spite of their
diography showed normal cardiac function.
structural resemblance, no case of TTP was reported in phase
III trials of clopidogrel with 19,185 patients.4 However, reports
Although TTP was considered in her differential diagnosis,
of clopidogrel-associated TTP have emerged since the FDA
her clinicans first attributed her microangiopathic hemolytic
approved the drug in 1998, including a seminal publication
anemia to suspected urinary tract infection. However, her
of eleven cases.5 Five of these cases passed an independently
status did not improve after several days with antibiotics and
conducted causality assessment.6 Despite the identification
with consultation from hematology, the diagnosis of TTP was
of additional clopidogrel-associated cases by pharmacologic
made at hospital day six. Serum von-willebrand factor (vWF)
7
surveillance, skepticism remains regarding whether clopidogrel
protease (ADAM-TS13) samples drawn during her hospital
8
actually causes TTP. Here we report a case of clopidogrelstay returned with an activity of < 5% (normal > 67%) by
associated TTP and briefly review proposed mechanisms of
fluorescence resonance energy transfer (FRET) assay, and >
drug-induced TTP.
8.0 inhibitory units by mixing (normal < 0.4), consistent with
immune-mediated TTP. The patient received a total of 8 units
Case Report
of packed red blood cells during her stay, and therapeutic
A 55-year-old Caucasian female presented with fever, jaundice,
plasma exchange was performed at hospital day #7 with 12
hematuria and painful neuropathy. Three years earlier, the
units of fresh frozen plasma (FFP). Twelve hours later, the
patient was diagnosed with colorectal cancer which was
successfully treated with resection. The patient also suffered
from severe peripheral vascular disease secondary to diabetes
mellitus, for which she had received an axillofemoral and
aortafemoral bypass grafts several years prior. Ten years earlier,
she also received a total abdominal hysterectomy with bilateral
salpingo-oopherectomy for an ovarian cyst. Her medications
at admission included coumadin 3 mg qday, premarin 0.3 mg
qday, hydroxychloroquine 200 mg qday, glucosamine, lisinopril
20 mg qday, hydrochlorothiazide 12.5 mg qday, cilostazol 100
mg bid, and clopidogrel 75 mg qday. Clopidogrel had been
added to her regimen within the past three months, ostensibly
as adjunctive therapy for lower extremity claudication. She was
an ex-smoker. She had no history of human immunodeficiency
virus (HIV) or quinine exposure.
Physical exam was significant for fever (38.0°C), mild jaundice
and petechiae of hands and abdomen. Laboratory testing

Figure 2. Peripheral blood smear at admission, 500x. Note
schistocytosis, severe thrombocytopenia, and polychromasia
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patient decompensated with acute shortness of breath and
hypotension, and was subsequently intubated and admitted to
the intensive care unit. Shortly after transfer, she entered into
pulseless electrical activity (PEA) and cardiac life support failed
to resuscitate her. Her family declined autopsy. No evidence
of fluid overload was seen. Based upon review of the events,
it is plausible that the patient died from a massive pulmonary
embolism likely secondary to her hypercoagulable state.

nor does the presence of ADAMTS13 antibodies guarantee that
a mixing test result will be positive. The latter situation is rather
easily explained by observing that protease-associated antibodies
need not necessarily inhibit the activity of the protease. The
former situation is more problematic, but fortunately appears
to be rare. In a rigorous cohort study of 35 TTP patients, Ferrari
et al.14 found that an immunoglobulin was present in 91% of
patients. Two of these patients had no detectable IgG/IgM/IgA

Discussion

With the addition of this case, there are now 38 identified
instances of clopidogrel-associated thrombic microangiopathy in the literature. The time course of drug initiation is
consistent with prior case series5 in which patients presented
with TTP within two to three weeks after beginning a thienopyridine-derivative.
Although our patient was also receiving a synthetic derivative
of quinine, no association has been made between hydroxychloroquine and TTP. In fact, thrombocytopenia alone is not
reported as an adverse effect of hydroxychloroquine therapy. It
is conceivable that the added hydroxychloryl group may alter
the epitope of quinine8 that induces drug-dependent antibodies.
Indeed, exquisite specificity has been demonstrated in other
causes of antibody-mediated drug-induced thrombocytopenia,
such as sulfamethoxazole9 and abciximab10. Drug-induced autoantibodies to ADAMTS13 may exhibit similar specificity, likely
accounting for the remarkably fewer cases of TTP documented
with clopidogrel compared to ticlopidine.
Plasma exchange treats TTP via two plausible mechanisms:
infusion and removal. Infusion of fresh donor plasma supplies
the patient’s circulation with the missing ADAMTS13 protease,
thereby breaking down dangerous excesses of von-Willebrand
factor multimers. Exchange of recipient plasma removes platelet
aggregates, vWF multimers, and inhibitory autoantibodies
to ADAMTS13. Plasma exchange may also filter culprit drug
metabolites which may have induced TTP, such as thienopyridine derivatives. Not surprisingly, it has been observed
that receipt of plasma exchange within three days of onset of
clopidogrel-associated TTP results in 100% survival, vs. 27% if
therapy is initiated afterwards.7 In our case, the fatality of our
patient may be attributable to delayed diagnosis and consequent
initiation of plasma exchange at hospital day seven.
The finding of a vWF multimer protease inhibitor in this case
is consistent with prior reports of ticlopidine and clopidogrelassociated TTP. Immunoglobulins to ADAMTS13 have been
found in other etiologies of TTP in which immune dysregulation
is suspected, such as human immunodeficiency virus (HIV)10
and solid organ transplantation.11 Inhibitory auto-antibodies to
vWF protease are almost always an IgG class, although IgA class
are occasionally identified in the same sera. The presence of an
ADAMTS13-activity inhibitor by mixing does not necessarily
mean that an associated immunoglobulin will even be detected;
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Figure 3. Endothelial cells secrete vWF multimers into the
circulation. The protease ADAMTS13 cleaves these multimers
at the A2 domain (A). Platelets adhere to these multimers in the
bloodstream (B) via the platelet glycoprotein Ib (GpIb). These
multimers can also bind platelets to the endothelial surface (C).
Deficiency or inhibition of ADAMTS13 causes vWF multimers to
accumulate. Multimer accumulation results in increased platelet
adherence and clot activation. This is the hypothesized mechanism
of TTP. (diagram from Sadler15)
but did have an ADAMTS13 inhibitor. Specialized clinical
laboratories have also reported occasional difficulty detecting
IgG with samples positive by mixing 16 . The inability to
detect immunoglobulin in these cases may simply represent
a functional limitation of the assay. Unfortunately in our
case, patient blood samples were disposed of before ELISA
could be performed to identify ADAMTS13 antigen and
immunoglobulins. Nevertheless, the strong inhibition of
ADAMTS13 in our sample ( >8.0 Bethesda units) makes it
likely that an immune-mediated TTP was present, mostly
likely secondary to clopidogrel. We also propose that
specialized hematologic laboratories implement protocols
to label and retain frozen blood samples of TTP for longer
periods than the conventional sixty days. This practice may
aid future investigators in the development of newer and
more effective tests for this rare disease.
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Case Reports

Man With Spontaneous Intracranial Hemorrhage on
Therapeutic Enoxaparin, Clopidogrel, and Aspirin
Mihir K. Patel, MD, Sumeet K. Chhabra, MD, Michael Pfeiffer, MD
Case Presentation

A 65 year-old Caucasian male originally presented to an outside
hospital complaining of worsening paroxysmal nocturnal
dyspnea, orthopnea, and recent exertional chest pain associated
with dyspnea. The patient’s past medical history was significant
for coronary artery disease status post coronary bypass, severe
aortic stenosis status post bioprosthetic aortic valve repair,
congestive heart failure, atrial fibrillation on anticoagulation,
dual-chamber pacemaker placement, history of a transient
ischemic attack, and type 2 diabetes mellitus. At the outside
hospital, coronary angiography revealed occlusion of native
vessels and previous grafts. He was considered a poor surgical
candidate. He was transferred to Thomas Jefferson University
Hospital (TJUH) for a second opinion regarding percutaneous
versus surgical intervention.
The patient’s initial hospital course was complicated by
persistent volume overload treated with aggressive intravenous
(IV) diuresis and atrial fibrillation refractory to medical therapy.
Electrophysiology service recommended elective transesophageal
echocardiogram (TEE) and electrocardioversion; TEE revealed
no left atrial clot, and the procedure was successful in restoring
sinus rhythm. Throughout his hospitalization, the patient was
maintained on weight-adjusted therapeutic low molecular
weight heparin (LMWH, enoxaparin), clopidogrel, and aspirin.
Other medications included amiodarone, atorvastatin, digoxin,
esomeprazole, ezetimibe, isosorbide mononitrate, metoprolol
succinate (XL), spironolactone, levothyroxine, niacin,
repaglinide, sertraline, and insulin.
Approximately two weeks after transfer to TJUH and two days
after cardioversion, the housestaff was called overnight for an
acute change in mental status and blurry vision. Upon evaluation,
patient was unable to respond to questions appropriately. He
complained of “not feeling well” and reported new bilateral
blurry vision. The patient and nursing staff denied any recent
trauma or fall. He was afebrile, normotensive (130/70) with
normal sinus rhythm (64 bpm), saturating well (98%) in no
respiratory distress (18 resps/min) with finger-stick blood
glucose of 93 mg/dL. Exam revealed the patient was oriented
only to person; Glasgow Coma Scale (GCS) on initial evaluation
was 14. Complete neurologic exam was non-focal: pupils were
equal in size and reactive to light and accommodation; visual
fields were intact bilaterally; cranial nerves II-XII were intact
and symmetrical; muscle strength was full in his upper and
lower extremities bilaterally; and his distal upper and lower
extremity sensation was intact and symmetric.
Stat head CT (Figure 1) revealed a large intraparenchymal
hemorrhage in the left parietal and temporal lobes, involving
the left lateral ventricle, third ventricle, and partial filling of right
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Figure 1.
Head CT without contrast shows a large intraparenchymal
hemorrhage in the left parietal and temporal lobes with
extension into the ventricles. Associated 7 mm left-to-right
midline shift with local mass effect is also observed.
lateral and fourth ventricles. A 7 mm left-to-right midline shift
with local mass effect in the left parietal lobe was also observed.
Repeat neurological exam immediately after report of these
findings remained non-focal, but the patient was notably more
lethargic. His eyes closed spontaneously but opened to voice,
and he responded to questions slowly and sometimes required
repeated questioning; GCS at this time was 13.
Neurosurgery evaluated the patient and arranged transfer to
the Neurological ICU for emergent right frontal ventriculostomy. Per consultation with hematology, the patient received
enoxaparin-adjusted IV protamine sulfate to attempt reversal
of therapeutic enoxaparin. The patient’s clopidogrel and aspirin
were also discontinued. The patient remained normotensive
throughout these events; however, his mental status and level
of consciousness continued to deteriorate rapidly. Despite
additional IV protamine sulfate, fresh frozen plasma, and factor
IX, the hematoma continued to expand as demonstrated by
repeat head CT (Figure 2) performed 10 hours after the initial
diagnosis. Further surgical options were discussed with the

strokes, and therefore, imaging is crucial. CT and MRI appear
to be equal in detecting an ICH, as well as determining size,
location, and extent of hematoma enlargement. Generally, CT
is superior in detecting ventricular extension, while MRI is
superior in detecting structural lesions, amount of surrounding
edema, and herniation.1 Because of the urgency associated with
a concern for ICH combined with the availability and duration
of MRI scans, CT is more commonly obtained.
Other aspects of the initial evaluation include obtaining vital
signs, laboratory studies, an EKG, and a chest x-ray. In a study
conducted by the Spanish Neurological Society, a temperature
greater than 37.5 C°, an elevated serum neutrophil count,
and an elevated fibrinogen level were all associated with early
neurological deterioration.2

Figure 2
On a repeat head CT performed ten hours later, there is significant
expansion of the left intraparenchymal hematoma and ventricular
hemorrhage, with increasing rightward midline shift. Interval
placement of a right frontal ventriculostomy catheter is noted.

patient’s wife. Considering the low likelihood of significant
functional recovery and her knowledge of the patient’s wishes,
surgical options were declined. He was subsequently placed on a
morphine infusion for comfort and expired the next evening.

Discussion

According to the American Stroke Association, intracerebral
hemorrhages (ICH) affected an estimated 67,000 individuals
in 2002, and only 20% of those individuals were expected to
be functionally independent six months after the event. The
30-day mortality of an ICH is reported to be 35 to 52%, with
the majority of deaths occurring within the first 2 days. Rapid
recognition is critical due to the potential for quick deterioration
of patients with this condition. The classic presentation is the
sudden onset of a focal neurological deficit that worsens over
minutes to hours. Other symptoms and signs include headache,
vomiting, and decreased level of consciousness. There is usually
a smooth progression of the neurological deficit over time. This
progression is uncommon in ischemic strokes and subarachnoid
hemorrhages. 1 Nevertheless, clinical features alone are not
sufficient to differentiate between ischemic and hemorrhagic

Patients diagnosed with an ICH need ICU level care along
with neurosurgical evaluation or transfer to a facility with
neurosurgical capabilities. The major aspects of medical
management for ICH involve controlling blood pressure,
decreasing intracranial pressure, and treating associated
conditions, such as hyperthermia, concomitant infections, or
hyperglycemia. Any anticoagulation should be immediately
discontinued or reversed if possible. Treating fevers with
antipyretics is valuable because lower body temperature lessens
tissue damage by redistributing oxygen and decreases glucose
consumption to permit relative tolerance to oxygen deprivation.
The data for treating hyperglycemia has been extrapolated from
the data on ischemic strokes. Hyperglycemia in the first 24 hours
(>140 mg/dL) after an ICH is associated with worse outcomes,
and current guidelines recommend the use of insulin for blood
glucose levels over 140 to 185. Ongoing research should provide
more specific information and clarify these guidelines.1
Treatment of elevated intracranial pressures should start with
simple measures such as elevating the head of the bed to thirty
degrees and keeping the head in midline position. If more
aggressive measures are needed, options include IV mannitol to
achieve plasma osmolality of 300 to 310 mosmol/kg, barbiturate
coma, or hyperventilation to a PaCO2 of 25 to 30 mm Hg. These
patients also need concomitant measuring of intracranial
pressure and blood pressure.1 Steroids should not be used as
they increase complication rates, particularly infection, and
have not been shown to improve outcomes.3 Many clinicians
also use antiepileptic agents for seizure prophylaxis. A study in
Italy aimed at characterizing ICH-related seizure revealed that
use of antiepileptic agents soon after ICH onset could reduce
the risk of early seizures.4 However, this benefit has yet to be
substantiated by prospective clinical studies.
There are no clear guidelines on how to manage elevated blood
pressure in ICH. On one hand, lowering the blood pressure
potentially slows hematoma expansion. On the other hand,
lowering blood pressure can also induce cerebral ischemia in
the edematous portions surrounding the hemorrhage. Current
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guidelines, as outlined in Table 1, recommend using continuous
IV infusion of antihypertensive agents for SBP > 200 or MAP
> 150 mm Hg, and either continuous or intermittent IV
medications for SBP > 180 or MAP > 130 mm Hg. Ongoing
trials are specifically evaluating the control of blood pressure in
patients with ICH.1
Table 1. Suggested Recommended Guidelines for Treating
Elevated Blood Pressure in Spontaneous ICH
1.

If SBP is >200 mm Hg or MAP is >150 mm Hg, then
consider aggressive reduction of blood pressure with
continuous intravenous infusion, with frequent blood
pressure monitoring every 5 minutes.

2.

If SBP is >180 mm Hg or MAP is >130 mm Hg and there
is evidence of or suspicion of elevated ICP, then consider
monitoring ICP and reducing blood pressure using
intermittent or continuous intravenous medications to keep
cerebral perfusion pressure >60 to 80 mm Hg.

3.

If SBP is >180 mm Hg or MAP is >130 mm Hg and there is
not evidence of or suspicion of elevated ICP, then consider
a modest reduction of blood pressure (e.g., MAP of 110
mm Hg or target blood pressure of 160/90 mm Hg) using
intermittent or continuous intravenous medications to
control blood pressure, and clinically reexamine the patient
every 15 minutes.

SBP indicates systolic blood pressure; MAP, mean arterial pressure
Broderick J, Connolly S, Feldman E, Hanley D, Kase C, Krieger D, Mayberg M, Morgenstern
L, Ogilvy CS, Vespa P, Zuccarello M. Guidelines for the Management of Spontaneous
Intracerebral Hemorrhage in Adults. 2007 Update: A Guideline From the American Heart
Association/American Stroke Association Stroke Council, High Blood Pressure Research
Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working
Group. Stroke 1 June 2007; 38(6): 2001-2023.

Recent studies are clarifying the risk of ICH and ICH-related
mortality associated with anticoagulation. Due to its predictable
and reproducible anticoagulant effects, LMWH has become
increasingly preferred over unfractionated heparin (UFH) for
anticoagulation in the inpatient setting. LMWH and UFH have
similar rates of major bleeding, 5 yet studies comparing LMWH
to UFH in patients with ST-elevation myocardial infractions who
have also received thrombolytics have shown an increased risk
of ICH in patients receiving LMWH over those receiving UFH.6
Predictors of anticoagulant-related ICH included coronary artery
disease, atrial fibrillation, history of ischemic stroke, and history
of pulmonary embolus or deep vein thrombosis. Patients with
anticoagulant-related ICH also had a higher mortality rates than
other ICH patients. The difference in mortality rates within the
first 24 hours post event in one retrospective review was 33.2%
in anticoagulant-related ICH versus 16.3% in patients with ICH
not on anticoagulation.7 Anti-platelet therapy is also associated
with worse clinical outcomes and is an independent predictor

for acute hematoma enlargement, rapid death, and need for
emergent hematoma evacuation.8
There is no proven method for reversing the effects of
LMWH. Unfractionated heparin and LMWH exert their
effects by binding to and catalyzing antithrombin III, which
inhibits certain coagulation factors, particularly factor IIa
and factor Xa. LMWH has a reduced ability to inhibit factor
IIa compared to UFH, but has a similar effect on factor Xa.
Intravenous protamine in animal studies and in vitro studies
significantly neutralizes the factor IIa activity of LMWH, but
only neutralizes 60% of its anti-factor Xa activity. Moreover,
studies demonstrating or refuting protamine’s beneficial
effect on LMWH-related bleeding in humans are lacking.
Nevertheless, in a patient who received LMWH within an
8 hour time window, the recommended approach is to
administer 1 mg of IV protamine for every 100 anti-factor Xa
units of LMWH. One milligram of enoxaparin is equal to 100
anti-factor Xa units. Therefore, a patient who received 80 mg
of subcutaneous enoxaparin within 8 hours should be given 80
mg of IV protamine. A second dose of 0.5 mg of IV protamine
per 100 anti-factor Xa units may be given if bleeding continues.
If LMWH was administered more than 8 hours ago, a lower
initial dose of protamine is recommended. For UFH, 1 mg of
IV protamine will neutralize 100 units of UFH.5

Conclusion

In summary, we have presented a case of severe intracerebral
hemorrhage in a patient receiving therapeutic enoxaparin
and antiplatelet agents. Initial suspicion for acute intracranial
hemorrhage was low based on non-localizing neurological
exam and lack of head trauma, but remained within the
immediate differential given the patient’s history and current
medications. The patient exhibited signs of slow global
neurologic deterioration, but his exam remained non-focal
throughout his hospital course. In this instance, radiographic
evaluation was pursued promptly. Although the intent was to
rule out, rather than confirm, suspected intracranial pathology,
radiographic imaging remained an integral part of the complete
patient evaluation.
Our experience suggests that while ICH classically presents with
focal deficits, the absence of focal deficits does not exclude the
diagnosis. It should remain high on any physician’s differential
while caring for a patient with an acute mental status change,
particularly in a patient on therapeutic anticoagulation or
antiplatelet medications. In managing patients with an ICH,
prompt neurosurgical evaluation is required. Additional
immediate attention should focus on controlling hypertension,
elevated intracranial pressure, hyperthermia, and hyperglycemia;
reversing anticoagulants if needed; and monitoring the patient
in an intensive care unit.
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Case Reports

Giant Negative T Waves

Siva K. Kumar, MD, Rajesh M. Kabadi, MD, Paul J. Mather, MD

Case Presentation

A 62 year old Caucasian man with a past medical history
significant for (long standing and controlled) HTN, lymphoma
(diagnosed 2 yrs ago and currently in remission), and diffuse
esophageal spasm presented to an outside hospital with expressive
aphasia and right sided weakness. He was treated with tissue
plasminogen activator (t-PA) for left MCA embolic stroke with
excellent clinical response with very minimal residual expressive
aphasia. Further work up and evaluation there revealed a large
left ventricular apical mass consistent with thrombus and he was
subsequently transferred to our facility for further evaluation
and management of this apical mass.

Hospital Course

On presentation, the initial physical exam was significant
only for an expressive aphasia. The presenting EKG, however
(see Figure 1), showed diffusely negative T waves in all leads,
especially in the left precordial leads.
The patient was asymptomatic and was initially started on
anticoagulation with heparin to bridge him to a therapeutic
INR on coumadin, given the report of thrombus. As part of
a workup here to further delineate and look at this area of
thrombus a transthoracic echocardiogram (see figure 2) was
obtained. This was read as showing an apical mass which was
reportedly 3.1 x 1.6 cm in size.

Despite the echocardiogram findings, there was still doubt as to
whether or not this was truly a case of apical thrombus, especially
since these are fairly rare. This clinical thinking combined with
the EKG findings, lead us to sequentially perform a nuclear stress
test to evaluate for the possibility of a silent MI as a cause of this.
This study was subsequently negative for any sign of ischemia.
Finally, for definitive diagnosis, a cardiac MRI was performed
to further evaluate the anatomy of the heart (see Figure 3). This
showed marked focal left ventricular apical thickening of 9 mm
likely corresponding to the abnormality seen on echocardiogram.
This region of thickening demonstrates signal intensity similar
to myocardium on all sequences and therefore is consistent with
focal apical hypertrophy.

Final Diagnosis
Left Ventricular Atypical Apical Hypertrophic Cardiomyopathy
(HCM)

Discussion
Apical HCM is an uncommon morphologic variant of HCM, and
accounts for probably less than 10% of all cases. First discovered
in Japanese males in 1976, it is most commonly seen in seen in
Asia and has been reported in 41% of patients in China and 25%
of patients in Japan.3

Figure 1. EKG–Normal sinus rhythm at the rate of 50 beats per minuts. Giant T wave negativity was evident, particularly in the left
precordial leads.
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Typical presenting features consist of an audible and palpable
fourth heart sound which reflects impaired ventricular
relaxation. ECG features include “Giant” T wave negativity in
the left sided precordial leads, as was the case with our patient.
Furthermore, imaging shows a “spade-like” configuration of the
left ventricular cavity at end diastole. Some patients may also
present with symptoms suspicious for ischemia such as chest
pain and dyspnea on exertion. This combined with the above
ECG findings will often lead to an immediate work up to rule
out infarction.

Figure 2. Transthoracic Echocardiogram. Overall normal
left ventricular systolic function with segmental wall motion
abnormalities. There is apical akinesis with a large (3.1 x 1.6 cm)
apical mass consistent with possible apical thrombus. A restrictive
mitral inflow pattern is seen associated with significantly elevated
left atrial pressure and reduced compliance of the left ventricle.

Figure 3. Cardiac MRI. Post-contrast T2 weighted image
demonstrating myocardial uptake of contrast. A thrombus would
not appear in such a manner as contrast material would not be
taken up.

There are multiple imaging techniques that can be used to
detect apical HCM, with the first line being non-contrast
echocardiography. The diagnostic accuracy of this modality is
limited, however, by the fact that the apex can often be difficult
to properly image. In many patients, the image seen may mimic
akinesia or apical thrombus with poor acoustic windows, as
was the case in our patient. In such cases, where the clinical
suspicion is strong, measures such as cardiac MRI or echo
with contrast may be more confirmatory.1 One study showed
that in 100 affected patients, traditional echo made the correct
diagnosis in 91% of patients, and the remaining nine were
diagnosed using MRI.4 A study by Pons-Llabdo, et al showed
that MRI allowed better overall assessment of the degree and
extent of LVH than echo did.5 In this same study it was stated
that MRI was able to properly visualize the apex in all patients,
while echo was successful in only 61%. Next to MRI, another
useful modality is contrast echocardiography which may have
better success than non-contrast with apical imaging. A case
report presented by Acarturk et al demonstrated the value of
contrast echo in diagnosing this condition.6 A final confirmatory
sign which is often seen on diagnostic catheterization is that of
the “spade like” configuration mentioned above. In most cases
this is an incidental finding as the primary purpose of cardiac
catheterization in this scenario is to evaluate for the possibility
of concurrent coronary artery disease given the symptoms of
chest pain and dyspnea on exertion that these patients will often
present with.3 Patients with this form of HCM will often present
at a young age and will be hospitalized due to symptoms and
EKG criteria suspicious for coronary artery disease, so proper
diagnosis can be of major importance. With a wall thickness of
9 mm, our patient would be classified as having a mild form of
this condition.
While the overall course of this condition is benign (especially
in Asian countries), approximately 1/3 of affected patients will
experience serious cardiovascular events such as myocardial
infarction or arrhythmia. In the asymptomatic patient with
no significant ischemia or arrhythmia, no specific therapy has
been outlined but counseling is certainly still recommended as
a precaution.4 Compared to patients with normal variant HCM,
there is a much lesser incidence of sudden cardiac death. The
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mainstay of therapy is symptomatic monitoring, with patients
being asked to inform their physician immediately in the event
of syncope or presyncopal symptoms. Interestingly enough,
there has been at least one published case of this condition being
associated with a multi-organ syndrome which also includes
atrial septal defect, hypothyroidism and renal failure.2 It is
unknown, at this time, whether or not this demonstrates any
sort of defined syndrome.
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Case Reports

Anomalous Origin of the Right Coronary Artery
Diagnosed by Cardiac Computed Tomography
Siva K. Kumar, MD, Faisal Shaikh, MD, Paul J. Mather, MD
Case Presentation

A 34 year old female with no significant past medical history
presented with intermittent left shoulder and chest pain. The
pain was burning in nature over her left chest and radiated to
her left arm. There were no alleviating or exacerbating factors.
Initial electrocardiogram showed sinus bradycardia. Cardiac
computed tomography angiography revealed anomalous
origin of the right coronary artery, which arises from the left
sinus of Valsalva (Figure 1) and then travels towards the right
side between the pulmonary outflow tract and the aortic root,
where it shows mild narrowing of about 50%, (Figure 2) for a
length of approximately 1 cm. The woman performed 9 mets
during her exercise stress nuclear test which demonstrated
electrocardiographic evidence of ischemia with normal
myocardial perfusion.

Discussion

Cardiac ischemia in this setting is presumed to be caused by
compression of the anomalous right coronary artery (RCA) as it
courses between the PA and the aorta during exercise. Coronary
artery anomalies are noted on approximately 1.3% of all cardiac
catheterizations. 1 Anomalous origin of the RCA from the left
sinus of Valsalva has been reported in approximately 0.03–
0.09% of patients undergoing coronary angiography. Although
previously considered to be a rare, but benign anomaly, more
recently it has been associated with myocardial ischemia,
infarction and sudden death in up to 30% of patients. 1-7 Patients
may be at risk for premature atherosclerosis. In the setting of
an obstructive lesion, these vessels are amenable to successful

Figure 2.
percutaneous coronary intervention and stent placement.8 The
patient has been asymptomatic for the past year while being
treated with beta blockers.
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Case Reports

A 42-year-old Male With Blurry Vision
William H Chong, MD, Dorothy Chang, MD

Introduction

Hypertension affects approximately 25% of the population
of the United States. Complications from hypertension
include ischemic heart disease and stroke, and rates increase
progressively as blood pressure increases.1 In some cases,
the elevation of blood pressure can be significant and be life
threatening. Situations where there is severe elevation of blood
pressure and evidence of target organ dysfunction are termed
hypertensive emergency. In this report, an unusual cause of
hypertensive emergency is presented.

Case Report

A 42 year-old male with no significant past medical history
presented to the emergency department after being seen at the
optometrist for a complaint of blurry vision and was found
to have markedly elevated blood pressure. He reported wavy
vision from his left eye as well as decreased peripheral vision
and decreased color vision. He noted 3 episodes of left-sided
headaches over the last month, but has otherwise felt well. He
reported no chronic medications, and no substance abuse.
Family history was significant for a brother with diabetes. Review
of systems was negative aside from the above-mentioned visual
changes. He reported no chest pain, no shortness of breath, no
abdominal complaints, and no urinary complaints. Physical
exam was significant for severe hypertension with blood pressure
of 245/115. Otherwise his exam was unremarkable. A report
from the optometry clinic noted that he had retinal changes
consistent with hypertensive emergency (Figure 1a, 1b).
The gentleman was admitted to the intensive care unit for
malignant hypertension. His admission labs were significant

Figure 1. 42 year old male presented to the optometry clinic with
complaint of blurry vision and was found to have retinal findings
consistent with malignant hypertension. (Images courtesy of
Wilmington VAMC)
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for a creatinine of 3.5 mg/dL. In addition to placing him on
a labetalol infusion for blood pressure control, work-up of his
renal failure revealed bilateral hydronephrosis and a massively
distended bladder rising above the level of the umbilicus (Fig
2a, 2b). Upon placement of a foley catheter and drainage of
retained urine, his creatinine began to improve and his blood
pressure became more manageable. Urologic evaluation
revealed urethral stricture. Subsequent clinical inquiries
revealed a distant history of urethral trama as a child which
had not been problematic previously. Work-up for other
causes of his malignant hypertension were unrevealing. The
cause of his hypertensive emergency was attributed to renal
failure secondary to urethral stricture. He was placed on oral
medications and instructed to perform clean intermittent
catheterization to prevent future urinary retention and was
discharged home. Outpatient discharge instructions included
urology & nephrology follow-up with a scheduled lumbar spine
MRI to evaluate for neurologic causes of urinary retention.

Discussion

Hypertensive emergencies are acute, life threatening, and usually
associated with marked increases in blood pressure, generally
above 180/120.2 Blood pressures elevated to this degree without
evidence of acute and progressive dysfunction of target organs is
termed hypertensive urgency. Most patients with hypertensive
emergency have had previously uncontrolled or unknown chronic
hypertension. However, the disorder can present in previously
normotensive individuals.3 In addition to marked elevation in blood
pressure, major clinical manifestations include retinal hemorrhages
and exudates, papilledema, and also malignant nephrosclerosis.

A. Right fundoscopic exam demonstrating a normal exam
B. Left fundoscopic exam demonstrating blurring of optic disc
(papilledema) consistent with malignant hypertension.

A

B

Figure 2. Following admission, pt found to have significant urinary
retention with renal failure and malignant hypertension believed to occur
secondarily. (Images courtesy of Wilmington VAMC)
A: Computerized tomography of abdomen demonstrating bilateral
hydronephrosis (arrows).
B: Massively distended bladder consistent with outflow obstruction
at the level of the umbilicus (arrow).

In assessing patients with severe hypertension to determine
if hypertensive emergency is present, certain history and
physical exam points should be emphasized. Medical history
should include previous treatments, illicit drug use, cardiovascular manifestations, neurologic symptoms, and urinary
habits. Eliciting information about other medical conditions,
such as thyroid disease, Cushing’s syndrome, systemic lupus
erythematosus, systemic sclerosis, abdominal pain, dyspnea, and
most recent menstruation can be extremely helpful.3 Physical
exam should also assess blood pressure measured in both arms
to detect any significant difference. Additionally, assessment
of peripheral pulses for absence or delay is of clinical utility.
Fundoscopy, cardiac and lung auscultation, and assessment of
mental status are also important. Target organ dysfunction can
be further revealed by analysis of laboratory studies and the
presence of any EKG abnormalities.
In treating hypertensive emergency, the main objective is to reverse
end-organ damage, which is accomplished by reducing mean
arterial pressure by up to 25%.3 In general, blood pressure should
be reduced by ~10% in the first hour and another 15% gradually
over the next two to three hours.3 This is best accomplished with
a continuous infusion of a short acting, titratable, parenteral
anti-hypertensive agent along with constant, intensive patient
monitoring.1 Anti-hypertensive drugs of choice include sodium
nitroprusside, nitroglycerin, nicardipine, fenoldopam, labetalol,
esmolol, hydralazine, and phentolamine. Co-morbidities and the
type of target organ dysfunction dictate which anti-hypertensive
agent should be selected.
In summary, this is a case of a 42 year-old male initially
presenting with blurry vision secondary to hypertensive
emergency. It is presumed that the etiology of this hypertensive
emergency episode was secondary to renal failure caused by a
urethral stricture. Hypertensive emergency is defined by severe
hypertension (usually above 180/120) and evidence of target
organ dysfunction. In these situations, prompt blood pressure
control by no more than 25% within the first several hours
prevents further end organ dysfunction. Numerous titrable,
anti-hypertensive agents exist and should be tailored to the
patient’s clinical history to prevent acute relative hypotension
and watershed infarct.
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Case Reports

Silent Assassin: Coronary Artery Disease
in a Type II Diabetic
Srinath Vemuri, MS IV, Neerav Sheth, MD
Case Presentation

A 53 year old white male with a past medical history significant
for type II diabetes mellitus and orthotopic liver transplant
(December 2006) secondary to hepatitis B cirrhosis presents as
a direct admission to Thomas Jefferson University Hospital in
September 2007 for an orthopedic preoperative risk evaluation.
Patient has had a dull, worsening, non-radiating back pain of six
months duration, beginning after his liver transplant for which
he has been to several outpatient orthopedic physicians. Upon
admission, the patient appeared well, but admitted to a consistent
8/10 back pain that he had been managing at home with narcotic
medications. Of note, outpatient magnetic resonance imaging
(MRI) showed diskitis at L4/L5. Spinal biopsy and cultures
were performed to rule out cord compression, spinal injury and
infection due to his previous surgery and were all negative. On
review of systems, he denied any lower extremity tenderness,
numbness, paresthesias or loss of bowel or bladder function. He
has lost over 70 pounds since his liver transplant. The remainder
of the patient’s past medical history was negative except for a
history of cataracts due to his diabetes mellitus. He reports a
strong family history of hypertension, coronary artery disease
and both type I and type II diabetes mellitus.
On physical examination, the patient was afebrile with stable and
normal vital signs. Cardiovascular exam demonstrated normal
S1 and S2 heart sounds, no murmurs, rubs or gallops, no jugular
venous distention, and no carotid bruits. His lungs were clear
bilaterally without wheezes, rhonchi, or rales. His abdomen did
have a clean, dry and intact Mercedes type scar indicative of his
liver transplantation. The remainder of his physical examination
was within normal limits. Admission labs (Complete Blood
Count, Basic Metabolic Panel, Electrolytes, PT/PTT/INR, Liver
Function Tests), chest X-ray, and EKG were all within normal
limits.
The patient was admitted to the general medical floor to
undergo risk assessment for the laminectomy procedure. As
part his cardiac evaluation, the patient underwent a nuclear
and exercise stress test that showed distal anterior and apical
hypokinesis. Cardiac catheterization was deemed necessary for
further evaluation. Cardiac catheterization demonstrated a 100%
RCA stenosis with significant stenoses in the LAD (70%), LCx
(70%), and OM1 (50%). In light of these findings, the patient’s
orthopedic procedure was delayed until cardiac revascularization could be achieved.

Discussion

This case illustrates a typical example of significant coronary
artery disease (CAD) in an asymptomatic diabetic patient. Type
II diabetes mellitus is a major risk factor for the development of
CAD. Moreover, it is considered a CAD equivalent. Similarly,
CAD is the major cause of morbidity and mortality in people

24

with type II diabetes.1 Atherosclerosis occurs earlier, has an
accelerated course, and is more extensive in diabetics compared
with the general population. 22 There are probably several
factors that contribute to this. Type II diabetes is associated
with abnormalities in lipoprotein metabolism and an increased
propensity for oxidative damage; the hyperglycemia of diabetics,
in itself, may accelerate vascular damage; and diabetes is a
hypercoagulable state attributable to enhanced coagulation and
decreased fibrinolysis, as well as platelet hyperaggregability and
endothelial dysfunction.33
The Insulin Resistance Atherosclerosis Study (IRAS) reported
finding considerably greater intima-media thickness in the
common and internal carotid arteries among patients with
established diabetes compared with non-diabetic subjects.44
Diabetic patients without previous myocardial infarctions (MI)
and non-diabetic patients with a previous MI have been found to
have equally high risk for MI. Diabetic patients also have a high
mortality rate from a first MI.55 These observations suggest that
diabetics without obvious CAD may still have extensive atherosclerosis that, if untreated, could lead to serious cardiovascular
complications. Some have suggested that this provides a rationale
for assessing and treating cardiovascular risk factors in diabetic
patients with the same aggressive approaches recommended for
non-diabetic patients with a prior MI.
Diabetes treatment protocols (diet, exercise, pharmacological
agents, and insulin) concentrate on controlling glycemia which
leads to CAD. However, glycemia is not as strongly associated
with macrovascular disease as it is with microvascular disease.
Macrovascular disease appears to result from dyslipidemia in
the diabetic patient. The form of dyslipidemia most frequently
observed in diabetics is characterized by increased triglyceride
levels and decreased high density lipoprotein (HDL) cholesterol
levels. Diabetics also tend to have a higher level of smaller,
denser low density lipoprotein (LDL) subclass pattern B than
non-diabetics due to increases in hepatic triglyceride lipase.66
Several studies have provided evidence of the link between
diabetic dyslipidemia and CAD.77 In diabetic patients who had
CAD events during a 7-year follow-up period had higher levels
of total triglycerides, LDL, triglycerides, and VLDL cholesterol,
and lower levels of HDL and HDL2 cholesterol than diabetic
patients who did not have such events. Other studies have found
that both high levels of apolipoprotein B (apoB) and small, dense
LDL among patients with high apoB levels also predict coronary
artery disease.
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Case Reports

Left Atrial Myxoma

Siva K. Kumar, MD, Rajesh M. Kabadi, MD, Paul J. Mather, MD

Case Presentation

A 65 year-old female with a past medical history of hypertension
and diabetes presented to her cardiologist’s office with symptoms
consistent with progressive heart failure over an eight month
period. A transthoracic echocardiogram done in the office
demonstrated a normal-appearing mitral valve and normal left
ventricular systolic function. Additionaly, it also revealed a large
left atrial myxoma (pictured above). The mass obstructed flow
through the mitral valve, resulting in a mean valvular gradient
of 18 mm Hg, consistent with mitral stenosis-like physiology.
As a result of these findings, the patient was admitted to our
institution for further evaluation. A transesophageal echocardiogram was performed for further assessment and showed a
6.7 x 4.6 cm homogenous mass which appeared to be attached
by a stalk to the interatrial septum at the fossa ovalis. The patient
subsequently underwent excision of this myxoma along with a
patch repair of the interatrial septum. Postoperatively she was
stable and discharged home six days later with surgical and
cardiac follow-up.

Discussion

Benign myxomas are the most common tumors arising in the
left atrium. Typically they are pedunculated and gelatinous
in consistency with size varying from 1 to 15 centimeters.
Cardiovascular manifestations largely depend on the anatomic
location of the tumor, with 80% being found in the left atrium.
Like our patient, ~70% of patients with left atrial myxoma suffer
symptoms of heart failure, as well as syncopal episodes. Nearly
30% suffer from embolic events.1
Once diagnosed, treatment involves prompt resection due
to the risk of potential embolization and/or cardiovascular
complications. Postoperative recovery is generally rapid.
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Figure 1. Transesophageal echocardiogram demonstrating a large 6.7 x 4.6 cm left atrial myxoma obstructing flow through the mitral valve.
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Case Reports

A 41-year-old Woman With Rheumatic Mitral Stenosis,
Atrial Fibrillation, and Right-sided Heart Failure
Stephen Koczirka, MS-III
Case Presentation

A 41 year old Southeast Asian woman presented to the Emergency
Department (ED) complaining of acute onset of nausea and
abdominal pain as well as a two weeks of palpitations and two
months of cough productive of white sputum. The patient
also complained of fever, shortness of breath and dyspnea on
exertion over the previous week. Patient history revealed a past
medical history of asthma. The patient had no prior surgical or
psychiatric history, had no known drug allergies, and consumed
no chronic medications. The patient reported that she had
immigrated to the United States from Laos in 1986. She denied
any tobacco, alcohol or illicit substance abuse.
The patient was afebrile and demonstrated hemodynamic
stability in face of her EKG demonstrating atrial fibrillation at a
ventricular response rate of 80 bpm. Lung auscultation revealed
bilateral crackles at the lower bases, but no rales or wheezing.
Cardiac examination demonstrated and an irregularly irregular
pulse with a mid-diastolic rumbling murmur heard best at the
apex without radiation. She demonstrated elevated jugular
venous distention to ~12 cm H2O and demonstrated 1+ pitting
lower extremity edema.
Laboratory data was significant for a beta-natriuretic peptide
(BNP) of 972 pg/mL. The patient had a microcytic anemia with
a hemoglobin 12.6 mg/dL. Troponins were all within normal
limits and the EKG did not reveal any ischemic changes. X-ray
findings, later corroborated by chest CT, demonstrated bilateral
pleural effusions, bilateral lower lobe infiltrates with mediastinal
and hilar lymphadenopathy. The patient was admitted to the
critical care unit for transesophageal echocardiogram (TEE)
which demonstrated:
The left atrium is severely dilated. The right atrium is moderately
dilated. There is moderate to severe tricuspid regurgitation.
Right ventricular systolic pressure is elevated at >60mmHg. Left
ventricular systolic function is borderline reduced. Flattened
septum is consistent with RV pressure/volume overload. The
right ventricle is mildly dilated. The right ventricular systolic
function is hypokinetic. There is severe mitral stenosis. The
mean gradient was 11 mm Hg and the peak gradient was 20
mm Hg. The valve area is 1.1cm2.
The results of the TEE suggested that the most likely etiology for
the patient’s valvular and clinical findings was that of rheumatic
mitral stenosis. The patient’s age, immigration status, and
relative lack of medical history also fit the prototypical model
of a patient with complications of prior acute rheumatic fever.
Possibly superimposed on this disease process is a bacterial
pneumonia causing the bibasilar infiltrates or these radiologic
findings which may simply have been an extension of the
sequelae of the rheumatic heart disease.

Discussion

Rheumatic fever is a delayed consequence of pharyngeal infection
with group A streptococcus (GAS). The disease manifestations
can affect several areas of the body, namely the cardiovascular,
musculoskeletal, neurological and dermatological systems. These
are believed to be a result of a diffuse inflammatory process
that results in an autoimmune attack on the body due to the
phenomenon of molecular mimicry. The GAS cell wall contains
M proteins that are antigenically similar to proteins found in
the human body. When an immune response is mounted to
the initial GAS infection, antibodies are formed against this M
protein, which then circulate throughout the body and bind to
normal protein epitopes in human tissue. The complexes formed
then induce a T-cell mediated attack on normal tissues, causing
the long term sequelae of the disease.1
Diagnosis of acute rheumatic fever has remained relatively
unchanged since it was first described in 1889 by William Cheadle
in London. In 1965, the American Heart Association released the
Jones guidelines, laying out a specific set of criteria to be used for
diagnosis.2 In 1992, the Jones criteria were revisited and revised,
and these guidelines are currently used in clinical practice:
Table 1. For diagnosis, two major criteria OR one major
criterion with two minor criteria is needed, in addition to
evidence of prior GAS infection
5 major manifestations:

4 minor manifestations

Carditis

Arthalgia

Migratory polyarthritis

Fever

Sydenham’s chorea

Elevated ESR or CRP

Erythema marginatum

Prolonged PR interval

Subcutaneous nodules
Evidence of preceding streptococcal infection:
Positive throat culture for GAS or positive rapid
streptococcal antigen test

Rheumatic carditis is considered to be the most serious of the
manifestation of GAS infection. It is very difficult to detect
before the disease is severe enough to become symptomatic.
The disease can manifest in any of the three layers of the
myocardium, but most often affects the cardiac valves, especially
the mitral valve (85% of affected patients). Small nodules known
as Aschoff bodies initially form on the valve leaflets and slowly
enlarge due to increased fibrin deposition. These deposits slowly
decrease the functional ability of the valve leaflets causing mitral
stenosis or mitral regurgitation, and functionally limit normal
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blood flow. Chronically, this leads to left atrial enlargement
(which can lead to atrial fibrillation), pulmonary hypertension,
and eventually right-sided heart failure.4 Natural history studies
suggest that the average amount of time from the onset of
rheumatic fever to onset of mitral valve symptoms is 16.3 years.
Further progression to severe mitral disability from the onset of
symptoms is 9.2 ± 4.3 years.
Treatment of rheumatic carditis is dependent on the extent
of the disease on presentation. If the cardiac damage is not
extensive, prophylactic treatment includes aspirin for mild
cases and steroids for more severe cases.4 In patients with severe
mitral regurgitation or stenosis, surgery is indicated to improve
blood flow through the cardiac system.5 It has been shown that
percutaneous balloon valvuloplasty and mitral valve repair
have shown similar initial results and efficacy at three years;
therefore, percutaneous balloon valvuloplasty is the preferred
surgical treatment due to better long term patency, lower cost,
and decreased need for open thoracotomy.6
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Patient Course

The patient’s atrial fibrillation was rate controlled with a
combination of beta-blockers and digoxin. She was bridged
from intravenous heparin to oral warfarin for anticoagulation
and her bibasilar pneumonia was treated with broad spectrum
antibiotics. She was transferred to another institution for
cardiothoracic evaluation of potential percutaneous balloon
valvuloplasty of the mitral valve.
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Case Reports

A Case Report of Idiopathic Giant Cell Myocarditis
Bao Bui, MD, Sumeet Chhabra, MD, Siva K. Kumar, MD

Case Report

A 32 year old African American male was admitted to an outside
hospital in July 2007 with symptoms of severe heart failure that
required implantation of a short-term left ventricular assist
device (LVAD). He was subsequently transferred to our facility
due to worsening left ventricular heart failure, episodes of
Torsades de Pointes, and monomorphic ventricular tachycardia.
His device was replaced with a longer-term LVAD and he
was discharged home in October. Fortunately, he underwent
successful orthotopic heart transplant in November 2007.
Surgical pathology of the explanted heart revealed widespread
cardiomyocyte necrosis, marked polymorphous inflammation,
and giant cell formation consistent with idiopathic giant cell
myocarditis (figures). Follow-up post transplant endomyocardial
biopsies did not reveal recurrence of giant cell myocarditis or
acute rejection.
Figure 2. Low power image (40x, H&E) showing clear delineation
of involved areas with inflammatory cell infiltration, giant cells, and
myocyte damage compared to relatively unaffected myocardium on
the left.

Figure 3. High power image (400x, H&E) showing a mixed
inflammatory cell infiltrate composed of eosinophils, plasma cells,
small lymphocytes, and multinucleated giant cells. Prototypical
multinucleated giant cell indicated by large thick arrow. Thinner
arrow shows associated myocyte damage.

Discussion

Figure 1. Gross image of left ventricular myocardium showing nodular, ovoid
tan-white areas (indicated by arrows) that microscopically corresponded to
the areas of inflammatory cell infiltration and myocyte necrosis.

Idiopathic Giant Cell Myocarditis (IGCM) is a rare and generally
fatal entity that has been largely confined to scattered case reports
and observational studies, most notably a multi-center registry
created by Cooper et al in 1997. While IGCM has historically
been a histological diagnosis at autopsy, the current gold standard
method of diagnosis remains endomyocardial biopsy. This
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disorder typically afflicts younger adults with mean age of fortythree.2 It is most commonly characterized by rapid and progressive
congestive heart failure generally refractory to conventional heart
failure treatments. Other common clinical presentations include
ventricular arrhythmias, heart block, and less commonly as early
symptoms of acute myocardial infarction.
While no uniform guidelines yet exist for the treatment of IGCM,
animal models suggest involvement of CD4 T-lymphocytes5,9
with reported success with combined steroid and immunosuppressive therapy.2,3,7 Reported associations with autoimmune
disorders are also consistent with this theory.1,6
Patients in the IGCM registry that received immunosuppression lived longer than those that did not.2 Heart transplantation also appeared to be efficacious with 5-year survival data
reported at 71% despite recurrence of disease in 20-42% of the
newly transplanted hearts.2,4,8 Our case of IGCM illustrates the
importance of surveillance biopsies and the growing evidence
that transplantation and immunosuppression may be effective
therapy for an otherwise rapidly fatal disease.
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Case Reports

Man With Flu-like Symptoms
Sandarsh Kancherla, MD, Ankitkumar Patel, MD, MPH

Case Presentation

A 69 year-old male presents to the Emergency Department
with complaints of malaise, myalgias, rhinorrhea, increased
congestion, and occasional fevers for one week. The symptoms
have gradually worsened over the past week, and Tylenol has
minimally alleviated his symptoms. He denies exacerbating
factors. He denies any trauma, shortness of breath, chest pain,
or recent weight change. He has no sick contacts or recent
travel history.
Past medical history is significant for coronary artery disease
status post myocardial infarction and coronary artery bypass
graft in 2000, hypertension, hyperlipidemia, and atrial
fibrillation. Medications on admission include amiodarone,
aspirin, atorvastatin, docusate, losartan, metoprolol succinate
(XL), and warfarin. He does not smoke, drink alcohol, or use
illicit drugs.
On admission, temperature was 99.7, blood pressure was 118/72,
heart rate was 74, respiratory rate was 18, and oxygen saturation
was 96% on room air. Physical examination was significant for
dry mucosa and mild proximal muscle weakness. Initial labs
on admission revealed an elevated creatinine of 1.9; CBC, UA,
and LFTs were within normal limits. The patient was admitted
with the diagnosis of upper respiratory tract infection with
dehydration and started on intravenous fluids and supportive
therapy for flu-like symptoms.
Approximately 3 days after admission, his rhinnorhea and
congestion had resolved, but he complained of worsening
myalgias. Physical exam at that time revealed worsening
tenderness to palpation over his shoulder muscles and
proximal lower extremities, as well as 4/5 muscle strength
in his quadriceps and deltoids. He had difficulty standing
from a seated position. Range of motion of all extremities
was intact. At that time, it was revealed that his atorvastatin
dose had been increased from 40 mg to 80 mg approximately
6 months ago as an outpatient. The CPK level drawn shortly
thereafter was 5,317, supporting a diagnosis of statin-induced
myositis, which is a form of drug-induced myopathy. Upon
discontinuing his atorvastatin, his symptoms improved, and
CPK trended down until it was within normal limits.

Discussion

Drug-induced myopathy is among the most common causes of
muscle disease. Symptoms range from mild myalgias with or
without mild weakness, to chronic myopathy characterized by
severe weakness, to massive rhabdomyolysis with acute renal
failure.1
Drug-induced myopathy results from direct myotoxicity from
lipid-lowering drugs and other agents such as alcohol, cocaine,
glucocorticoids, antimalarials, and colchicine. 2 Statins are

considered effective and generally safe, but experience in clinical
practice suggests that muscle side effects are relatively common;
some of the side effects are severe enough to warrant discontinuation of statin therapy.
The mechanism by which statins cause muscle toxicity is not
well understood. They inhibit the conversion of HMG-CoA to
mevalonic acid, which is an important early step in cholesterol
synthesis. Statins can also decrease the synthesis of coenzyme
Q10 (CoQ10), which plays an important role in muscle cell
energy production.3 This pathway is thought to contribute
tostatin-induced muscle injury.
The onset of muscle symptoms is usually within weeks to months
after the initiation of statin therapy. Typically, the presentation
of statin-induced myopathy is very non-specific. It has a very
insidious onset and includes progressive weakness, generalized
pain, and fatigue. Myalgias and weakness generally resolve, and
serum creatinine kinase levels return to normal within days to
weeks upon discontinuation of statin therapy.
The muscle symptoms in patients taking statin therapy can range
from mild symptoms to severe symptoms. The incidence of mild
myalgias, defined as muscle ache or weakness without increases
in CPK levels, in patients taking statins ranges from 2 to 11
percent.4-5 Symptoms generally resolve within 2 to 3 weeks after
stopping a statin. Myositis, defined as a serum CPK elevation
more than 10 times normal in association with muscle symptoms,
occurs in less than 0.5% of patients.4-5 Rhabdomyolysis resulting
from severe muscle destruction is rarely seen and occurs in less
than 0.1 % of patients.6 Rhabdomyolysis has primarily been
seen when a statin is given concurrently with cyclosporine or
gemfibrozil.7
The risk of muscle injury due to statins appears to vary among
the different drug formulations. The risk of myopathy is lowest
with pravastatin (less than 0.1%) and fluvastatin.8 These two
medications are also less likely to cause drug interactions since
they are not extensively metabolized by CYP3A4. Patients
with acute or chronic renal failure, obstructive liver disease,
and hypothyroidism have increased susceptibility to statinassociated myopathy.
The risk of myopathy is much greater in patients who are also
taking drugs that inhibit CYP3A4, must notably cyclosporine,
gemfibrozil, macrolide antibiotics, itraconazole, and HIV protease
inhibitors. These drugs increase the serum concentration of the
statins. Initial studies of lovastatin and simvastatin showed
clinically significant myopathy in 13 to 30% of patients taking
cyclosporine.4 Approximately 5% of patients taking atorvastatin
or lovastatin in addition to gemfibrozil experience significant
myopathy.4,9 In contrast, pravastatin and fluvastatin, which are
not metabolized by CYP3A4, do not appear to increase the risk
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of myopathy when given with cyclosporine.10,11 This is a very
important consideration when treating transplant patients.
Routine monitoring of CPK levels is not recommended, but
it is useful to obtain a baseline serum CPK before initiation
of statin therapy for reference. Patients should be alerted to
the potential side effects of statins and report new onset of
myalgias or weakness to their physician. CPK levels may be
abnormal in conditions such as hypothyroidism, trauma, and
high impact sports. In general, a CPK level more than 10 times
the upper limit of normal, in the absence of other clinical risk
factors, is generally felt to be due to a statin. It is an indication
to discontinue the medication. If a patient experiences muscle
myopathy on a statin, with the exception of rhabdomyolysis,
the statin should be discontinued until symptoms resolve. It is
reasonable to consider restarting pravastatin or fluvastatin with
careful monitoring. In the case of rhabdomyolysis, the statin
should be discontinued indefinitely. If muscle toxicity occurs
while on pravastatin or fluvastatin, a trial of CoQ10 supplementation may be initiated, although there is only limited evidence
for its benefit.12
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Case Reports

A 22-year-old Woman With Systemic Lupus
Erythematosus Develops Cardiac Tamponade
Brooks Kuhn, MS-III, Arthi Reddy, MD, Sorin Lazar, MD
Introduction

Systemic lupus erythematosus (SLE) is a common cause of
pericardial effusion and acute pericarditis, but very rarely
it can cause cardiac tamponade.1 We describe the case of a
young female with SLE who developed cardiac tamponade
after finishing treatment for acute pericarditis with a small
pericardial effusion.

Case Report

A 22-year-old college student at a local university with a history
of SLE diagnosed in 2003 (ANA+, anti-dsDNA+, and anti-SSA+) presented to an outside hospital complaining of shortness
of breath, fever, and pleuritic chest pain. These symptoms began
acutely in the presence of a week-old lupus flare characterized by
a butterfly malar rash and arthralgias. A chest CT demonstrated
a small pericardial effusion without evidence of tamponade.
She was diagnosed with pericarditis and subsequently her
outpatient dose of prednisone was increased from 15 mg/day to
60 mg/day. However, she showed little clinical or radiographic
improvement on CT. She was then scheduled to receive pulse
dose steroids (methylprednisolone) for 3 days.
The patient presented to our hospital on Day 3 after her initial
presentation to the outside hospital with continuing complaints
of shortness of breath, though without chest pain or fever. Her
past medical history was significant for multiple hospitalizations
for pleuritis and pericaditis, most recently seven months prior
for pericarditis. That episode had resolved after a three day
course of pulse steroids. Vitals demonstrated a temperature of
98.4o F, a pulse of 79 bpm, a respiratory rate of 20/min, and
a blood pressure of 118/70. Physical exam illustrated a rash,
symmetrically distributed across the malar aspects of her
face. Her exam including cardiac auscultation was reportedly
benign. An echocardiogram showed the persistence of a small
pericardial effusion and mild left atrial enlargement. A chest xray revaled bilateral pulmonary edema with bibasilar atelectasis
and cardiomegaly. EKG and laboratory tests were within normal
limits except for an elevated ESR and CRP. The patient was
promptly started on pulse steroids for three days.
Despite completing her course of steroids, repeat transthoracic
echocardiography visualized persistence of a small pericardial
effusion. A repeat chest CT to evaluate her pleural effusion
imaged a 2.1 cm dense lesion in the right upper quadrant of her
lung. PPD and an acid-fast bacilli (AFB) stain were negative.
A bronchoalveolar lavage did not demonstrate any purulent
secretions or notable AFB stains. Clinically, the patient had
markedly improved, denying shortness of breath, chest pain,
and cough. Nevertheless, empiric antibiotic therapy with
vancomycin and piperacillin/tazobactam was initiated.
On the evening of Day 8, the patient began complaining of
severe chest pain. On examination, she had visible jugular

venous dilation to her mandible and pulsus paradoxus of
approximately 10 mm Hg. She was tachycardic at 109 beats
per minute, blood pressure was 92/60, and her respiratory rate
was 25 resps/min. A stat echocardiogram revealed markedly
increased pericardial fluid causing IVC collapse with mitral
valve inflow respiratory variation. The right heart was not
collapsed. EKG showed sinus tachycardia with T-wave
flattening in V5, V6, and aVL. The patient was immediately
taken to the cardiac catheterization lab for pericardiocentesis. A total of 680 cc of yellow, purulent fluid was
drained with staining revealing gram positive cocci in clusters
which eventually grew methicillin-sensitive Staphylococcus
Aureus (MSSA) on culture. Vancomycin was continued and
piperacillin/tazobactam was discontinued. Two days later
the patient received a pericardial window to prevent further
episodes of effusion and tamponade. Vancomycin was initially
narrowed to nafcillin but after developing a bout of acute renal
failure this was changed to cefazolin. Despite a complicated
hospital stay, she was discharged home in good health.

Discussion

Cardiac tamponade is a known complication of SLE, albeit a
very rare manifestation.1 More typical cardiac manifestations of
SLE include pericarditis and pericardial effusion, as seen in our
patient, along with myocarditis, endocarditis, and conduction
abnormalities. 2 Causes of pericardial effusions include
idiopathic, viral, bacterial, uremic, traumatic, or neoplastic
pathologies. In connective tissue disorders, effusions are most
typically caused by inflammatory cell infiltrate and immune
complex deposition within cardiac tissue, causing a serous or
serosanguanous exudate similar to synovial fluid to encompass
the heart.3 This pericarditis and effusion can be significant, but
rarely causes pericardial tamponade.3 When it does, it tends to
occur in males later in life.4
While rare, it is not necessarily surprising that the patient
presented here developed cardiac tamponade early in life. There
are numerous published case reports which detail SLE patients
developing tamponade, even as their presenting symptom.5,6 This
case is noteworthy due to the bacterial etiology of her pericardial
effusion & tamponade. A similar case was presented by Knodell
et al. in Chest 1974 which chronicled a female with known SLE
who presented with fever, chills, and a significant pericardial
effusion, but without positive blood cultures.7 It was only when
thoracentesis revealed a Staphylococcal effusion that the source
of her infection was found after steroid treatment on her 11th
day of hospitalization. The patient described in our case differs
in that she remained afebrile throughout the course and did not
show any tell-tale signs of infection until her chest CT revealed
the cavitary lesion in her lung. It is unusual for such a significant
infection to remain relatively asymptomatic throughout its
course. The origins of our own patient’s pericarditis remain
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elusive. Obviously, her lengthy course of steroids contributed to
her infection, but no source could be identified apart from the
loculated lesion in her lung.
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Case Reports

Hemochromatosis
Benjamin Creelan, MD

Case Presentation

This 50 year-old adult male suffered from iron overload due
to repetitive blood transfusions for HbSS sickle cell anemia.
Computed tomography (CT) scan of the abdomen revealed
high attenuation and massive enlargement of the liver consistent
with hemochromatosis. A normal liver and spleen is included
for comparison (inset). Splenic calcification is also noted, a rare
finding in sickle cell anemia.1,2
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Discussion

Secondary hemochromatosis causes reticuloendothelial cell
iron deposition. The disease has homogeneously increased liver
attenuation on CT and decreased signal intensity with magnetic
resonance imaging. Portal vein branches stand out as lowattenuation structures against the background of the hyperattenuating liver. Other deposition diseases such as amiodarone
toxicity may create a similar appearance.3 In iron overload
states, there is a direct correlation between liver intensity on CT
imaging and serum ferritin.4

Inset: Normal abdomen for comparison.
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Case Reports

A 70-year-old Male With Abdominal Pain
William H Chong, MD

Introduction

Acute pancreatitis is an acute inflammatory process of the pancreas.
It is usually associated with severe acute upper abdominal pain
and elevated blood levels of pancreatic enzymes.1 Serum amylase
and lipase are common tests obtained as biochemical markers
for acute pancreatitis.2 Pancreatitis, however, is not the sole
cause of elevated pancreatic enzymes. Non-pancreatic causes of
hyperamylasemia include inflammation or trauma to the salivary
glands, bowel perforation or infarction, renal failure, abdominal
trauma, and macroamylasemia.2 An unusual cause of elevated
pancreatic enzymes is reported in this case report.

Case Presentation

A 70 year old male was admitted to the hospital after being
evaluated by his primary care physician for abdominal pain. He
initially complained of abdominal pain and had labs and x-rays
ordered from the office. After 2 days, he called for results and
was admitted to the hospital for abnormal lab studies.
At admission, he described his pain as dull and achy, located
primarily in the right upper quadrant. Initially the pain was
rated a 7/10 in severity, but had improved to 2/10 by the time
of admission. The only treatment he had used over this period
was ibuprofen. His symptoms were worse with deep inspiration,
and he noted no other symptoms such as nausea, vomiting,
constipation, or diarrhea.
His past medical history was significant for benign prostatic
hypertrophy, hyperlipidemia, coronary artery disease, reflux,
and vitiligo. Past surgeries included appendectomy and hand
surgery. He had no allergies and the only medication that he
was taking was terazosin. Social history was negative for alcohol,
tobacco, or drugs, and family history was non-contributory.
Review of systems was otherwise unremarkable.
On physical exam he was in no acute distress and his vital
signs were stable. Cardiovascular and pulmonary exam were
unremarkable. Abdominal exam was significant for tenderness
to palpation in the right upper quadrant over the rib cage, but
a negative Murphy’s sign. Labs and studies obtained from his
physician’s office were significant for a serum amylase level
of 699 units/dl. Other labs including complete blood count,
electrolytes, and lipase were all within normal limits. X-rays of
his ribs and spine showed no evidence of fractures.
His physician admitted him with concern for pancreatitis.
Further studies obtained while admitted to the hospital
including abdominal ultrasound and CT scan showed no
evidence of pancreatitis or gallstones. Serial amylase levels
continued to be elevated throughout his hospitalization. His
pain was attributed to chondritis from having moved furniture
prior to initial presentation. An amylase-creatinine clearance
ratio was calculated and found to be low at 0.2%, consistent with
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macroamylasemia, and his elevated amylase level was attributed
to macroamylasemia.

Discussion

The typical presentation of acute pancreatitis includes an
elevated serum amylase level and steady, severe upper abdominal
pain radiating to the back.3 For patients with acute pancreatitis,
hospitalization is almost always required. Management includes
bowel rest, IV hydration, pain management, supportive care, and
serial laboratory tests to monitor for improvement or worsening
of the patient’s condition. However, not all elevations in amylase
are related to pancreatitis.
In 1964, Wilding et al reported a condition found in three
patients with persistently elevated serum amylase levels. These
patients were found to have amylase-globulin complexes that
were too large to be readily excreted by the kidney. In 1967,
Berk et al reported a condition in the New England Journal
of Medicine which he termed macroamylasemia. Aside from
immunoglobulins, the amylase molecule can also bind to
polysaccharides forming these enlarged complexes. The size of
the complex prohibits renal excretion and results in persistently
elevated levels of amylase. Several diseases have been described
in association with macroamylasemia, including celiac disease,
HIV infection, lymphoma, ulcerative colitis, rheumatoid
arthritis, and monoclonal gammopathy.2 However, macroamylasemia does not have to be associated with these disease states
and can occur in any condition in which abnormal immunoglobulins are present.
Diagnosis of macroamylasemia can be made by applying a
simple diagnostic algorithm.3 The initial step is to evaluate for
elevated serum lipase. If this is also elevated, acute pancreatitis
should be strongly considered. The next step is to then measure
urinary amylase. If it is elevated, acute pancreatitis should
again be strongly considered. If neither of these is the case and
renal function is abnormal, secondarily elevated amylase due
to renal disease should be considered. Once these causes have
been eliminated, isoamylase testing to exclude non-pancreatic
sources of amylase can be performed. If the amylase is indeed
pancreatic in origin, the amylase-creatinine clearance ratio can
be calculated using the formula:
Urine Amylase x Serum Creatinine x 100
Serum Amylase Urine Creatinine
If this is found to be less than 1% macroamylasemia should be
suspected. If desired, further analysis can be performed with
electrophoresis, polyethylene glycol precipitation testing, and
gel chromatography.
Acute pancreatitis needs to be suspected in any patient with
abdominal pain and elevated pancreatic enzymes. These

symptoms, however, need not be related and other causes
for elevated pancreatic enzymes should be considered. Nonpancreatic sources of enzymes and other causes for increased
release of pancreatic enzymes should be considered. In addition,
decreased clearance of enzymes can create elevated serum levels.
Decreased clearance can be due to impaired renal function, or
abnormal amylase-globulin complexes that can not be readily
excreted. An example of the latter is presented here as a case of
a patient with abdominal pain and elevated amylase.
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Case Reports

Trust Your Gut

Roger Coron, MD, Jennifer Hurd, MD, Steven Ludwin, MD, Patricia Kozuch, MD

Case Presentation

MG is a 56-year-old female with no significant past medical
history who presented to TJUH in October 2007 with a two
year history of abdominal pain and weight loss. At presentation,
she described her pain as non-radiating, 7 out of 10, gnawing,
burning and located in the epigastrum and left upper quadrant.
The pain initially occurred approximately 15 minutes postprandially and lasted 30 minutes. Over the two year period, the
pain progressed to lasting for hours following meals. Dietary
modifications and food consistency did not help the pain. The
patient began avoiding oral intake, and her weight declined
from 120 to 80 pounds. She denied nausea, vomiting, diarrhea,
constipation, hematochezia, melena and change in stool
frequency. Over the two years prior to admission the patient
had an extensive workup with multiple gastroenterologists.
Her initial workup included a colonoscopy, EGD, abdominal
ultrasound and computerized tomography (CT) of the abdomen
and pelvis. These were all reportedly normal and the patient was
diagnosed with irritable bowel syndrome and treated symptomatically with a PPI. Due to lack of improvement, a second gastroenterologist repeated the EGD/colonoscopy and diagnosed her
with peptic ulcer disease secondary to multiple gastric ulcers.
She was treated with a PPI and carafate. A capsule study showed
gastric and jejunal ulcers with cobblestone appearance of the
small bowel which led to the diagnosis of Crohn’s disease. She
was treated briefly with Pentasa. The patient sought care as an
outpatient at TJUH Division of Gastroenterology. Mesenteric
ischemia was initially high on the differential. An MRA of the
abdomen revealed patent mesenteric vessels. Other workup
included gastric emptying scan, push enteroscopy, endoscopic
ultrasound (EUS), full-thickness biopsy in the operating room,
fasting gastrin level, and an NSAID level. These studies were
mostly inconclusive. Other studies including an octreotide scan,
gastrin levels, and chromogranin A levels were either normal
or inconclusive. Furthermore, it was discovered that the gastric
pH was 4.4, arguing against a gastrin producing tumor as seen
in Zollinger-Ellison Syndrome.
At the time of admission, her medications were pantoprazole 40
mg BID and ciprofloxacin 500 mg BID, both of which offered
only mild relief. She has a 25 pack year smoking history, does not
drink alcohol or use other drugs. Her family history is significant
for a brother and father having coronary artery disease. On
examination the patient appeared thin and pale. The abdomen
was not tender to palpation, however, an abdominal bruit could
be auscultated. Admission labs were within normal limits except
for a WBC count of 12,000 without a left shift. The question
of mesenteric ischemia was again entertained. An abdominal
ultrasound with dopplers revealed a greater than 70% stenosis of
the superior mesenteric artery (SMA). CT angiography (CTA)
of the abdomen revealed occlusion of the celiac artery, near
occlusion of the SMA, and stenosis of the inferior mesenteric
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artery (IMA). The magnetic resonance angiogram (MRA) done six
months earlier was post-processed and finally revealed stenosis of
the SMA. Vascular surgery was consulted and a decision was made
to pursue traditional angiography and stenting by interventional
radiology. Interventional radiology placed 2 overlapping stents
in the SMA which subsequently demonstrated excellent filling of
the SMA and branches. Since adequate collateral circulation was
observed, the celiac artery was not treated. The post-procedure
course was complicated by thrombosis of the left brachial artery
prompting thrombectomy. Approximately two weeks after her
procedure, the patient had no abdominal pain, is eating voraciously
and had already gained 5 pounds.

Discussion

Chronic mesenteric ischemia (CMI) can be distinguished from
acute mesenteric ischemia by the time course of the symptoms and
etiology of the disease. Acute mesenteric ischemia can be caused by
four mechanisms: SMA embolus or thrombosis, acute mesenteric
venous thrombosis, and non-occulsive mesenteric ischemia.1 The
focus of this article will be chronic mesenteric ischemia. Common
risk factors include hyperlipidemia, diabetes, and smoking.2
Although there are many possible causes of CMI, most commonly
it is secondary to atherosclerosis.2 The celiac artery (CA) and
SMA are the most commonly affected, although the IMA can be
involved. Due to the slow development of the stenosis, particularly
when atherosclerosis is the etiology, patients may develop collateral
circulation to the affected vessels. Often symptoms do not develop
until two vessels have become occluded. Symptoms commonly
include post-prandial pain beginning ~15-60 minutes after food
ingestion and last ~1-4 hours, manifest by sitophobia, weight loss,
nausea, and vomiting. Involvement of the CA distribution may
also cause gastroparesis, gastric ulceration, and even gallbladder
dyskinesia. While both physical exam and common laboratory tests
are usually unremarkable, it is common for patients to have cachexia
and stigmata of vascular disease including an abdominal bruit.2
Traditional angiography has been the gold standard for
diagnosis of CMI. Recently, however, duplex ultrasonography
(US), CTA, and MRA are increasingly used to evaluate
compromise of the mesenteric arteries. Duplex US is more
accurate in identifying SMA stenosis (90%) in comparison to
CA stenosis (80%). Areas of stenosis are identified by increases
in peak systolic or velocity of blood flow (CA>200cm/s,
SMA>275cm/s).7 Results may be affected by variations of body
habitus, bowel gas, respiration, and anatomy.2
CTA and MRA are also reliable methods for the diagnosis of
CMI.4 In the presence of a negative CTA study (particularly the
multidetector-row CTA), it is unlikely for the patient to have
CMI. MRA can identify greater than 90% of SMA lesions, 7590% of CA lesions, and 25% of IMA lesions.2 Furthermore,
some studies have reported 100% sensitivity of diagnosing

Figure 1. SMA before stent placement.
CA and SMA stenosis when compared to the gold standard of
invasive angiography.2
When two or more mesenteric vessels are occluded or
significantly stenosed in the setting of post-prandial abdominal
pain and weight loss, there are two therapeutic options. In
the past, surgical revascularization used to be the only option
available. This involved transaortic endarterectomy or antegrade
vs. retrograde bypass surgery. One study showed a 93% success
rate for endarterectomy with a high patency rate at 1 and 3
years. Unfortunately, many of the patients requiring revascularization are malnourished and at higher risk for perioperative
complications. Complication rates range from 15-33% with
mortalitiy up to 17%.3
The other therapeutic option for CMI is percutaneous angioplasty
(PCA) with or without stent placement. Unfortunately, it is
difficult to compare this modality to surgery. A study involving
25 patients revealed that clinical benefit at 11 months was 91%
and patency of the stents was 92%.5 Furthermore, the mean
complication rate for endovascular therapy is 10% with a
mortality rate up to 5%.3 Overall, it appears that endovascular
repair may have less associated morbidity and mortality,
however surgery offers the benefit of a lower re-stenosis rate.6
Finally, it should be emphasized that this case reiterates the
importance of clinical history in diagnosis. This patient’s
diagnosis was initially prolonged despite a fairly classic history,
hence CMI was not entertained. However, a false negative MRA
further delayed her diagnosis. Furthermore, the authors point
out that this patient should never have been diagnosed with
irritable bowel syndrome. The diagnosis of IBS can be made
using the Rome criteria. Weight loss is a red flag and should
have excluded this diagnosis.

Figure 2. SMA after stent placement.
While imaging and laboratory tests are generally very useful in
assisting clinicians make diagnoses, these results should never
supercede clinical acumen.

Key Points

Postprandial abdominal pain and weight loss are the typical
symptoms seen in chronic mesenteric ischemia (CMI).
1. Usually, 2 of the 3 major mesenteric vessels must be
occluded before the patient develops symptoms.
2. Diagnosis can be made by MRA, US with dopplers,
or CTA.
3. Treatment options include vascular surgery and
endovascular stenting.
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Case Reports

Chest Pain as a Presenting Symptom for Gastric Phytobezoar
Ankitkumar K. Patel, MD, MPH, Sandarsh Kancherla, MD, Darren Seril, MD

Introduction

Chest pain is a common chief complaint of patient presentation
to the emergency room. It also presents itself as one of the most
challenging symptoms for clinicians to manage. The differential
diagnosis for chest pain involves a multitude of organ systems.
Failure to recognize potentially serious life-threatening causes
such as acute ischemic heart disease, aortic dissection, tension
pneumothorax, or pulmonary embolism can lead to serious
morbidity and mortality. At the same time, overly conservative
management of low-risk patients leads to unnecessary hospital
admissions, studies and procedures. 1 The following case
illustrates the need to broaden the differential diagnosis for chest
pain once life-threatening causes have been ruled out (Table 1).

Case Presentation

The patient is a 55 year old female with a past medical history
of spinal fusion, chronic back pain, gastroesophageal reflux, and
anxiety who was in her usual state of health prior to admission
when she started having crushing chest pain that radiated to
the left arm. The patient was resting when the pain first awoke
her and was of 8/10 constant intensity. The pain was associated
with diaphoresis and nausea. The patient took ranitidine at first
onset, but this provided no relief. The patient came into the
emergency room eight hours after onset of chest pain because
she was feeling fatigued and lightheaded at work.
In the emergency room the patient’s pain went from 8/10 to
4/10 with the administration of sublingual nitroglycerin and
omeprazole.
The patient’s past surgical history included hysterectomy,
cholecystectomy, and breast reduction. The patient’s family
history includes: mother with ovarian cancer, father with
heart disease, and a brother with heart disease and 3 stents.
The patient has a 40 pack year history of smoking cigarettes,
occasional alcohol consumption, no illicit drug use and works
as a cashier. The patient stated that due to the significant
family history of heart disease and her significant smoking
history, she had started eating a “heart healthy” diet consisting
predominantly of fruits and vegetables. The patient had no
known allergies. Medications on admission were omeprazole,
celecoxib, naproxen, acetaminophen/hydrocodone, cyclobenzaprine, zolpidem, alprazolam, and varenicline.
On presentation, the patient was afebrile (97 o F) with EKG
demonstrating normal sinus rhythm (72 bpm), blood pressure
100/58, saturating 100% on room air with no respiratory
distress noted (16 resps/min). The cardiopulmonary physical
examination was within normal limits. Initial laboratory studies
including a complete blood count and chemistry panel were
within normal limits. A recent nuclear thallium stress test 2
months prior showed no ischemia and a LV ejection fraction
of 60%.
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The patient was admitted to the general medicine service. Serial
troponins were negative. Hemoglobin A1C level was 5.5%. A
fasting lipid panel had triglycerides of 351 mg/dL, HDL of 34
mg/dL and total cholesterol of 211 mg/dL. A chest x-ray showed
no active pulmonary disease and a normal cardiac silhouette.
The patient underwent a nuclear thallium gated stress test which
showed no exercise induced reversible myocardial perfusion
defects, increased lung uptake (most likely secondary to COPD
or smoking history), no evidence of regional wall motion
abnormality and a calculated left ventricular ejection fraction
of 58%.
The patient’s pain was diminished but had not been obliterated.
A cardiology consultation suggested the patient be ruled out for
pulmonary embolism. Though the patient did not demonstrate
normal signs and symptoms of a PE, a CTA was performed which
showed no signs of aortic dissection or pulmonary emboli. After
a negative cardiac workup, the patient underwent endoscopy to
investigate whether her symptoms were secondary to gastrointestinal pathology. The endoscopy found a medium sized
phytobezoar in the stomach compatible with gastroparesis and
mild antral gastritis. A gastric biopsy was taken for investigation
for H. pylori. The phytobezoar was not removed.
The patient was discharged with a diagnosis of gastroparesis
secondary to gastric phytobezoar with subsequent initiation of
metoclopramide therapy. In addition to her previous outpatient
medications, we added ezetimibe and simvastatin for hypercholesterolemia. Six weeks later, the patient reported no further
episodes of chest pain.

Discussion

Traditionally, bezoars were valued as cures for disease. The name
derives from the Arabic word for “antidote.”2 Bezoars come in
three varieties: phytobezoars, comprised of vegetable material;
trichobezoars, formed from hair; and lactobezoars, composed of
milk.3 Phytobezoars, the most common type of bezoar found in
adults, are formed from the cellulose and lignin found in fibrous
fruits and vegetables, most commonly oranges, figs, apples,
persimmons, green beans, and brussel sprouts.4 Medications
and supplements, such as coated aspirin, sucralfate, and vitamin
C, are also known to form bezoars.
Most bezoars reside in the stomach but can be found anywhere
in the gut.5 The formation of bezoars is typically associated with
altered stomach physiology. Disturbances in gastric motility
or gastric acid production, as well as poor mastication, are
predisposing factors. Bezoars commonly arise in individuals
following gastric surgeries (vagotomy, gastrectomy), and
dementia or mental retardation (particularly in the case of
trichobezoars).2

Many bezoars are asymptomatic, so the reported cases
underestimate the prevalence in the population. Bezoars were
found in 0.4% of patients in two large endoscopic series.6
The main risk factors for bezoar formation are abnormal
mastication, vegetarian diet, ingestion of persimmons, gastric
operation, diabetic gastroparesis and hypothyroidism.7 The
patient described above had started a vegetarian diet.
Most cases are asymptomatic and therefore go undetected.
Presenting symptoms vary depending on the site of concretion
formation. Bezoars are most commonly formed in the stomach,
but may also arise in the esophagus, small bowel, and rectum.
Reported findings include dysphagia, abdominal pain,
nausea and vomiting, early satiety, bloating, anorexia, weight
loss, halitosis, constipation, and gastrointestinal bleeding. 8
Phytobezoar impaction has been known to cause gastric outlet
obstruction, and distal migration of gastric bezoars can cause
small bowel obstruction and associated symptoms. Bezoars
are capable of serving as the nidus of common bile duct stone
formation.9 Physical exam may reveal a palpable abdominal
mass. Imaging studies, including plain radiographs, ultrasound,
and barium studies, may be useful in the diagnosis of bezoars.
On CT, bezoars appear as ovoid, “mottled-appearing” or “feceslike” (gas-containing) masses.10 Endoscopy can definitively
identify a concretion, while at the same time providing
therapeutic options.
Treatment options include medical management, endoscopy,
and surgery. Surgical approaches, laparoscopy or laparotomy,
are reserved for cases where medical and endoscopic modalities
fail.11 Endoscopy provides a variety of tools for the removal of
bezoars, including mechanical disruption with biopsy forceps,
polypectomy snares, and baskets, lithotripsy, and lasers.12
The endoscopic approach also permits the direct injection of
proteolytic enzymes into the concretion. Medical management
includes the use of proteolytic enzymes such as papain and
cellulase, gas expanders, and mucolytics (N-acetylcysteine). 13
Coca-cola, administered via either endoscopic injection or
lavage, has been reported effective in the management of
bezoars. The sodium bicarbonate content and low pH of Cocacola have been cited as possible mechanisms of action. Other
carbonated beverages would likely be just as effective.14,15
The presentation of chest pain, as in the present case, is not
typical of symptomatic bezoar and is not reported elsewhere in
the literature. Gastric phytobezoars often present with epigastric
abdominal pain, and esophageal bezoars can cause dysphagia
and associated coughing and vomiting.16,17 It is well established
that gastrointestinal processes, most notably gastroesophageal
reflux disease (GERD) and esophageal spasm, can mimic chest
pain related to ischemic heart disease. Indeed, GERD is the
most common alternative explanation for the complaint of
chest pain (Table 1). Esophageal bezoars are known to form in
the setting of altered esophageal pH and GERD and there are

reports of gastric bezoars impacting in the esophagus following
episodes of vomiting.18 However, as mentioned above, the usual
manifestation of such an esophageal obstruction is dysphagia.
It is certainly possible that the bezoar in the present case was
an incidental finding and was unrelated to the patient’s chest
pain.
On follow up 2 months later, the patient reported no more
episodes of chest pain. The resolution of the chest pain
symptoms with removal of the bezoar would be suggestive
of an association, but would certainly not be conclusive. It is
well known that chest pain due to esophageal spasm can be
ameliorated by nitroglycerin, as in the present case. In addition,
the patient has a history of GERD, which may provide another
explanation for her symptoms. The relationship between gastric
bezoars and gastroesophageal reflux has not been reported.
Table 1. D
 ifferential Diagnosis of Patients Admitted
to Hospital with Acute Chest Pain Ruled Out
for Myocardial Infarction
Diagnosis

Percent (%)

Gastroesophageal reflux disease

42

Ischemic heart disease

31

Chest wall syndrome

28

Pericarditis

4

Pleuritis/pneumonia

2

Pulmonary embolism

2

Lung cancer

1.5

Aortic aneurysm

1

Aortic stenosis

1

Herpes zoster

1

Adapted from: Fruergaard P, et al. European Heart Journal. 1996, 17:1028.
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Case Reports

Foreign Body in the Small Intestine
Benjamin Creelan, MD

Case Presentation

This adult was working on a ladder during a home restoration
project. She placed the bit in her mouth while changing the
screwdriver bit, then fell from the ladder and inadvertently
swallowed the bit. In the emergency room, her review of systems
and laboratories were unremarkable. Imaging revealed the bit
to be within the duodenal lumen and after four days of serial xrays, the bit was retrieved by snare colonoscopy at the ileocecal
junction. The patient remained asymptomatic and had no
complications.

Discussion

Although most ingested foreign bodies will pass through
the gastrointestinal system unaided, 10-20% may require
endoscopic intervention, and less than 1% will require surgery.1,
2
Erosion, obstruction, and perforation are more likely to occur
at regions with sharp angles or narrowing, particularly the
upper esophageal sphincter and ileocecal junction.3 Endoscopic
retrieval of foreign bodies should be employed for any object
that has failed to pass through the esophagus after 24 hours due
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to the high risk of perforation.3, 4 Fever, vomiting, or abdominal
pain demands a prompt surgical consultation. If endoscopic
retrieval is unsuccessful, laparoscopy may be employed.5 Snare
or forceps endoscopy should be avoided in cases where rupture
of the foreign body may be fatal, such as in concealed colonic
narcotic packets, a practice called “body packing.”1, 6
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Case Reports

Acuphagia
Saurabh Bansal, MD

A 29 year old male with a history of sw allowing objects
and recent abdominal surgery presented to the emergency
department (ED) after “accidentally” swallowing a pen. A
chest radiograph was performed that verified the presence of
the pen. The gastroenterology service performed an emergent
EGD to remove the pen. Six hours after the procedure the
patient signed out against medical advice. The patient returned
to the ED 10 days later with complaints of hematemesis that was
unwitnessed by any medical staff. On laboratory evaluation
his hemoglobin was the same as the previous admission.
Psychiatry subsequently interviewed the patient and found he
had gone to Hahnemann Hospital after swallowing a knife and
was subsequently transferred to a Psychiatric facility after being
medically cleared with no knife having been found or retrieved
from the patient’s abdomen. After re-presenting to Jefferson he
left against medical advice once again.
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Case Reports

Vocal Cord Dysfunction in Asthmatics
Yvonne L. McCarey, MD

Case Presentation

A 44 year old female with a past medical history of type 2
diabetes, hypertension, congestive heart failure, coronary artery
disease, 2 strokes, 2 myocardial infarctions, questionable history
of pulmonary embolus twice, bipolar disorder, schizophrenia,
and multiple asthma exacerbations presented to the Emergency
Department (ED) with SOB and wheezing. Her symptoms began
at home earlier that day and were not improved by bronchodilators. On arrival to the ED, she was lethargic in severe
respiratory distress with laboring accessory muscle use. She
had only an allergy to latex. Outpatient medications included
albuterol inhaler, fluticasone/salmeterol inhaler, inhaled
budesonide, furosemide, and warfarin for empiric treatment of
an unidentified hypercoaguable disorder. She reported having a
15 pack year smoking history including marijuana and cocaine
use up to several days prior to admission, but she denied any
prior alcohol or intravenous (IV) drug abuse. Family history was
non contributory. Her respiratory distress prohibited a thorough
review of systems on admission, but the rest of her history was
obtained through family at the time of arrival. They related that
she had described some chest tightness earlier.
Vitals revealed the patient to be afebrile, tachypneic (26 resp/
min) saturating 100% on room air with her other hemodynamic
parameters within normal limits. Significant inspiratory and
expiratory wheezing were auscultated on exam and despite
treatment with magnesium sulfate, bronchodilators and IV
steroids, her respiratory distress did not improve. She was
emergently intubated for the 6th time in her life. Laboratory
studies were significant for a normocytic anemia with a
hemoglobin 8.5 mg/dL and a urine drug screen revealing the
presence of cocaine. Otherwise, she had a normal metabolic
panel, coagulation studies, d-dimer, normal troponins, and no
EKG changes to support an ischemic event.

Hospital Course

The patient rapidly weaned off the ventilator and was extubated
within 7 hours. Notably, her peak inspiratory pressures ranged
from 23-26 mm Hg. Her steroids were rapidly tapered and
scheduled nebulizer treatments were regularly delivered. She
was discharged home without any further complication several
days after admission.

Discussion

This patient carries a diagnosis of asthma with repeated
intubations in our hospital’s Emergency Department resulting
in multiple hospital stays per year. While it is not infrequent
for a severe asthma attack to require intubation, certain features
are usually present, including the observation of increased peak
airway pressures once ventilated. In the case presented here,
the patient’s peak airway pressures were normal, intubation
rapidly relieved symptoms, and the patient recovered quickly.
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This scenario is consistent with Vocal Cord Dysfunction (VCD)
sometimes referred to as Paradoxical Vocal Cord Motion
Disorder (PVCMD), Laryngeal Dyskinesia (LD) or a host of
other terms, which can occur alone or in conjunction with
asthma. In an acute state this condition can closely resemble
an asthma attack and may therefore go unrecognized for years
leading to wasted healthcare dollars for unnecessary intubations
not to mention the delayed delivery of appropriate treatment.
Demographics include a 2:1 female to male predominance with
71% of cases being adults above age 18. The disorder does affect
neonates, however, though this is believed likely secondary to
gastroesophagela reflux disease (GERD).4
During an attack, the vocal folds adduct during inspiration
and/or expiration leading to dyspnea, wheezing, cough, chest
pain and stridor. Once thought to be psychogenic, evidence
is growing to support mechanisms of glottic hypersensitivity
secondary to various stimuli including GERD, chemical irritants,
upper respiratory infection, and exercise. Altered autonomic
balance, stimulation of the sensory nerve endings in the upper
or lower respiratory tract, hyperventilation and hypocalcemia
are also thought to play a role.2 It is important to rule out
neurologic causes of VCD including brainstem compression,
stroke, myasthenia gravis, amyotrophic lateral scerlosis, and
focal dystonias.4
Clinical features distinguishing the disorder from asthma
include irritant, exercise, and anxiety induced symptoms
especially those refractory to usual asthma treatments. Lack
of nocturnal awakenings and sputum may also be important
clues. In addition, wheezing heard loudest over the larynx or
larger airways, a normal alveolar-arterial gradient, and normal
oxygen saturation, as in this patient, may help distinguish
between the two. Recently, however, several cases of VCD have
been observed in the setting of hypoxemia. 2 Laryngoscopy
remains the gold standard of diagnosis. During an attack of
VCD, laryngoscopy will reveal adducted vocal cords. However,
during an asthma attack, the vocal cords will not be adducted.
Pulmonary function tests may be normal when asymptomatic
but will show a flattening of the inspiratory and/or expiratory
limb while affected. Unfortunately, methacholine challenge
can induce VCD symptoms and cannot reliably be used to
distinguish between asthma an vocal cord dysfunction.1,4
The similarity of symptoms and the difficulty distinguishing
between VCD and asthma poses a challenge for clinicians
responding to a patient in severe respiratory distress as presented
above. In the acute setting, does the clinician intubate the patient,
despite the increased chance of ventilator associated pneumonia
and likely prolonged hospital stay? Or does the clinician risk the
possible consequences of not intubating a severe asthma attack?
It is likely that most clinicians would stay the conservative route

of intubating the patient rather than attempting to discern the
two entities and risking disastrous consequences.
Once VCD is adequately diagnosed several treatments can
be used, even during an acute setting. The anxiety created by
the patient hearing their own wheezing can be minimized by
reassurance and judicious use of benzodiazepines. Heliox is
the non-commercial name for a unique mixture of helium and
oxygen that reduces air density therefore reducing turbulence
in the airway, and in turn reducing the work of breathing and
possibly relieving symptoms. 4 Similarly, using a mask with
a one-way pressure valve increases resistance to inspiration
which will reduce stridorous sounds and diminish the
patient’s distress. Continuous positive airway pressure (CPAP)
presumably improves symptoms by slowing expiratory flow and
increasing lung volume resulting in a more open glottis. Inhaled
anticholinergics, likely through a vagally mediated mechanism
have been shown to prevent exercise induced symptoms in case
reports only. Interestingly, botulinum toxin type A has also
been reported as useful treatment to prevent attacks.2

The aforementioned techniques may be utilized in the treatment
of patients strongly suspected to suffer from VCD with the
objective of avoiding repeated intubation and the consequences
of steroid over-use. Many patients will improve with proper
treatment. Long term treatment aimed at preventing attacks
involves regular follow up with ENT, Pulmonary, Psychiatry
and importantly a speech therapist to optimize control of the
laryngeal muscles and proper breathing techniques.
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Case Reports

Immunocomprised Heart Transplant Patient With
Cryptosporidial Diarrhea
Michael Dominic Lee, MSIII, Rajesh Kabadi, MD, Siva K. Kumar, MD
Case Presentation

A 22 year-old female with a past medical history of postpartum
cardiomyopathy status post orthotopic heart transplant (OHT)
was admitted for diarrhea of 12 days’ duration. The diarrhea was
watery, non-bloody, and occurring at a rate of 10 episodes per
day. She denied nausea, vomiting, fever, or chills, but reported
abdominal cramps. On physical exam, she was afebrile, and
vital signs were stable. The patient had a regular heart rate and
rhythm. Lung sounds were clear to auscultation bilaterally. Her
abdomen was soft, non-tender, without rigidity, guarding, or
distention. There was no edema in the extremities.
Laboratory studies were all within normal limits. The patient’s
CMV quantitative analysis, adenovirus culture, CMV culture,
blood cultures, fecal culture and C. difficile EIA tests were
negative. In addition, serum antigens for Rotavirus, Entameoba
Histolytica, Giardia, and Cryptosporidium were negative.
Finally, a flexible sigmoidoscopy was performed to define the
etiology of her diarrhea and demonstrated erythematous mucosa
in the sigmoid. Biopsies were taken in the sigmoid mucosa and
the colon. Five days later, the biopsies in both the sigmoid
mucosa and colon revealed the presence of scattered organisms
suspicious for cryptosporidium.
Before the results of the biopsies were back, the decision was
made to discontinue the patient’s mycophenolate mofetil
(Cellcept®). Mycophenolate mofetil is normally part of the
immunosuppressant regimen used to prevent rejection in
organ transplantation. One of the common adverse effects of
mycophenolate mofetil is diarrhea. Holding mycophenolate
mofetil had the added benefit of lessening its suppressive effects
on the patient’s immune system. After the discontinuation of

the mycophenolate mofetil, the patient’s diarrhea finally began
to abate to less than two episodes of semi-watery diarrhea per
day. The patient was able to tolerate an oral diet and no longer
had abdominal cramps. The patient was discharged a day later
with instructions to discontinue mycophenolate mofetil.

Discussion

Cryptosporidium is an intracellular protozoan parasite that is
recognized as a major cause of diarrhea in immunosuppressed
hosts. This includes patients with HIV, organ transplantation,
IgA deficiency, hypogammaglobulinemia, and on immunosuppressive therapy. In the United States and Europe, 8-30% of HIV
patients excrete Cryptosporidium oocysts, and in developing
countries, this figure climbs to 15-50%, making it one of the
most common enteropathogens. 1 The prevalence in HIVnegative, immunocompromised patients is unclear.
Diagnosis of Cryptosporidiosis can be tricky because there are no
characteristic laboratory findings indicative of Cryptosporidium
infection other than identification of the organisms. As a result,
the diagnosis is primarily based on microscopic identification of
the oocysts in stool or tissue. Other sites to look for the organisms
include duodenal aspirates, bile secretions, biopsy specimens
from affected gastrointestinal tissue, or respiratory secretions.
Diagnosis is also complicated by the low sensitivity of ova and
parasite tests in stool. In one report, examination of a single
stool specimen identified only 30% of intestinal Cryptosporidial
infections.2 Therefore, it is recommended to test three stool
specimens before excluding the diagnosis of Cryptosporidiosis.
Finally, there is currently no reliable therapy for Cryptosporidiosis.
Recovery from Cryptosporidiosis is based upon the immune
status of the patient. Immunologically competent patients
usually have a spontaneous recovery within a few weeks
without requiring any specific therapy. For immunocompetent
children, nitazoxanide is the drug of choice. For HIV-infected
patients, the recommendation is to initiate HAART in order to
restore immune system function. Restoration to a CD4 count
> 100 cells/microL is associated with complete resolution of
symptoms.3 There are currently no recommendations regarding
how to treat HIV-negative, immunocompromised patients.
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Case Reports

Infliximab-Induced Interstitial Lung Disease in a Patient
With Psoriatic Arthritis
Lan Quang, MD, Anthony Scarpaci, MD
Introduction

Infliximab (Remicade, Centocor, Inc., Malvern, PA), a chimeric
monoclonal antibody derived from both murine and human
antibody sequences and directed against TNF-α, is one of the
disease modifying anti-rheumatic drugs (DMARDs) used in
the treatment of psoriatic arthritis and other autoimmune
inflammatory conditions such as rheumatoid arthritis,
ankylosing spondylitis, and Crohn’s disease. It is commonly
used in combination with methotrexate for increased efficacy
and reduction of the development of anti-infliximab antibodies.
A concerning feature of infliximab therapy is its association with
an increased risk of infection or reactivation of diseases that can
cause pulmonary complications, most notably tuberculosis and
fungal infections. Additionally, there are a number of patients
who have developed non-infectious interstitial lung disease
following treatment with infliximab. These events usually occur
after the second to third infusions and can be preceded by a
course of methotrexate. In the setting of prior methotrexate
therapy, it is suggested that infliximab may potentiate the
manifestations of pulmonary toxicity due to methotrexate,
specifically methotrexate pneumonia.1 In the following case
report, we cite an example of the development of interstitial
lung disease after infliximab therapy in a patient with psoriatic
arthritis.

Case Presentation

A 59-year-old female with a previous medical history of asthma
and psoriatic arthritis with recent infliximab therapy presented
to the Emergency Department (ED) with a chief complaint of
progressive shortness of breath for two weeks. She experienced
chest tightness and dyspnea with exertion. She denied wheezing
and received minimal relief with nebulizers. She also stated
the presence of subjective fevers and sweating that started two
weeks ago. She denied leg swelling, weight gain, recent trips,
or sick contacts. Upon examination, she had difficulty speaking
due to shortness of breath and had rales on her left lung. No
wheezing or jugular venous distention was noted. She required
2 liters of oxygen by nasal cannula to maintain her saturations
at 96%. Cardiac examination was within normal limits. The rest
of the patient’s exam was normal. Initial chest x-ray was read as
prominence of interstitial lung markings.
Additional pertinent medical history includes: psoriatic
arthritis diagnosed 7 months prior to admission for which she
had received prior treatment. She had received intra-articular
steroid injections into the hand joints. After that therapy did
not relieve her symptoms she received two doses of weekly
methotrexate. This therapy was discontinued due to patient
intolerance. The patient began infliximab therapy three months
later. She had received three infusions of infliximab on a
biweekly schedule. The last infusion was administered two weeks
prior to admission. Her medications at presentation included:

metoprolol succinate (XL) 50 mg po qday, fenofibrate 145 mg
po qday, omega-3-fatty acid 4g po qday, irbesartan 150 mg po
qday, ezetemibe 10 mg po qday, rosuvastatin 20 mg po qday,
diphenhydramine 50 mg po qhs, furosemide 20 mg po qMWF,
fluticasone/salmeterol 250/50 mcg diskus day, alprazolam 1 mg
po qhs PRN, oxycodone/acetaminophen 5/325 mg po PRN, and
albuterol nebulizers PRN. The patient stated that she develops
seizures from gabapentin.
The patient’s medical and surgical histories also included: HTN,
hyperlipidemia, mitral valve prolapse, history of supraventricular tachycardia, anxiety, steroid-induced diabetes mellitus,
steroid-induced psychosis, thyroid cysts, MRSA pneumonia,
ocular surgery, ulnar nerve surgery, and breast lump removal.
Her social history is significant for drinking 2-3 alcoholic
beverages per week and no use of tobacco or recreational drugs.
She is normally fully functional and lives alone. She works for
a newspaper publisher.
Pertinent positives on review of systems included: chest
tightness, shortness of breath, cough, hoarseness, and epistaxis.
Pertinent negatives on review of systems included: no sputum
production, wheezing, edema.

Assessment

In the ED, the patient was treated with albuterol nebulizers.
After no improvement in her symptoms, the patient was
admitted to telemetry for further cardiac and respiratory
evaluation. Acute MI was ruled out with three negative
troponins and an unremarkable EKG. Echocardiogram showed
normal left ventricular size and function, an ejection fraction of
70 percent, and mild impaired relaxation of the left ventricle.
Her symptoms did not resolve with supplemental oxygen and
nebulizer treatment. Moxifloxacin was started for empiric
antibiotic coverage for community-acquired pneumonia. Room
air arterial blood gas was within normal limits. Despite this
laboratory value, the patient desaturated while ambulating on
room air to 77%. Chest CT (Figure 1) showed interstitial lung
disease with mild to moderate congestive heart failure. Despite
diuresis with furosemide, the patient’s symptoms did not resolve
so bronchoscopy was performed. Bronchoalveoloar lavage was
negative for malignant cells, PCP, fungus, and mycobacterium.
Transbronchial biopsy (Figure 2) was consistent with active
pneumonitis with interstitial inflammation, edema, and fibrosis.
Air spaces were lined by type II pneumocytes and contained
macrophages, fibrin and organizing pneumonia, which are
features consistent with drug-induced pneumonitis.

Management

The patient’s radiologic studies and pathology are consistent
with drug-induced pulmonary toxicity. After extensive review
of her medications, it was felt that the only drug that was
temporally related to the patient’s symptoms was
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infliximab. After nebulizers, antibiotics, and diuresis failed to
provide symptom relief, the patient was started on prednisone
50 mg orally daily. She was discharged 7 days after admission
on a prednisone taper and maintained on two liters portable
oxygen with mild improvement in her symptoms.

Discussion

Recent literature has implicated infliximab in the development
of interstitial pneumonitis.1 Many of the cases are in patients
with rheumatoid arthritis or Crohn’s Disease. 1,2 Often,
rheumatoid arthritis patients are concurrently receiving
methotrexate therapy to maximize disease modification.
Notably, the pulmonary toxicity can be quite severe. A prior
case series reports four patients with interstitial pneumonia and
one patient with bronchiolitis obliterans organizing pneumonia
following infliximab therapy. The patients had rheumatoid
arthritis and were not treated with methotrexate due to preexisting lung disease. Each of the patients except the patient
with bronchiolitis obliterans experienced rapidly declining
hospital courses and eventually expired from respiratory failure
despite steroids and ventilatory support.3

Figure 1. High Resolution Chest CT: Cross-section demonstrating
diffuse bilateral groundglass opacities and pulmonary edema.

The pathophysiology of infliximab induced pneumonitis is not
known. One possible theory is that infliximab may potentiate
the pulmonary toxicity of methotrexate. However, this does
not account for patients who were not receiving methotrexate
therapy. Animal models of bleomycin-induced lung toxicity have
shown that blocking TNF-α worsens toxicity. Other research
has shown that inhibition of TNF-α may increase proinflammatory cytokines. Additionally, when infliximab binds to TNFα on CD-4+ T cells and macrophages, proteolytic enzymes are
released which can lead to pulmonary damage.3
This is the first reported case of interstitial pneumonitis due to
infliximab in the psoriatic arthritis population. Our patient’s
exposure to methotrexate was limited to only a short treatment
of two doses, which was terminated secondary to intolerance.
Thus, the lack of a prior therapeutic methotrexate regimen and
the temporal relationship of the development of lung symptoms
with the start of infliximab infusion suggest that infliximab
alone may have induced interstitial lung disease.
As pulmonary complications associated with infliximab are
further documented, it becomes important to screen patients
for risk factors for pneumonitis prior to initiating therapy.
Some of the identified risk factors specifically for methotrexate
pneumonitis include preexisting lung disease, older age, diabetes,
hypoalbuminemia, and previous use of DMARDs.4
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Figure 2. H&E stain of tissue sample from transbronchial lung
biopsy. The above slide demonstrates active pneumonitis with
interstitial inflammation, edema, and fibrosis. Airspaces are
lined by type II pneumocytes and contain macrophages, fibrin
and organizing pneumonia.
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Case Reports

A Man With Abdominal Pain and Acute Renal Failure
Faisal Shaikh MD, Marina Serper, MD

Case Presentation

A 33 year-old African American male with a past medical
history significant for HIV on HAART therapy presented
to the emergency department (ED) with acute onset of right
upper quadrant abdominal pain and mild shortness of breath.
The abdominal pain was not associated with any fevers, chills,
nausea, vomiting or diarrhea. The patient denied any chest
pain, palpitations, lightheadedness or syncopal episodes. He
did report some dysphagia with solids more than liquids over
the last 2 months as well as decreased oral intake. His review of
systems was otherwise significant for weight loss which he was
unable to quantify.
He denied any medication allergies. His medications on admission
included trimethoprim/sulfmethaxazole, azithromycin,
fluconazole, lopinavir/ritonavir, and emtricitabine/ tenofovir.
His most recent CD4 count was 114 cells/mm3 and he had no
other known past medical history.
On initial physical exam, the patient was found to be tachycardic
at 115 bpm, hypotensive with a blood pressure of 80/40 mm
Hg, and tachypneic exhibiting 32 resps/min. The head and
neck exam were significant for oral thrush. Other than resting
tachycardia, the cardiovascular exam was unremarkable. The
pulmonary exam was notable for tachypnea, but the lungs
were clear to auscultation and there was no observed accessory
muscle use. The abdominal exam was significant for tenderness
to palpation in the right upper quadrant without rebound or
guarding. The patient was alert and oriented and had no focal
neurological deficits.
Admission labs were notable for a white blood cell count of
19.3 cells/μL with 22% bands, creatinine 1.8 mg/dL (no baseline
available), total bilirubin 1.8 mg/dL, direct bilirubin 1.2 mg/dL
with an alkaline phosphatase of 1233 IU/L. AST and ALT were
90 U/L and 64 U/L, respectively. The patient was also noted to
have a lactate of 86.7 mEq/L.

Hospital Course

The patient responded to 3L normal saline fluid resuscitation
to 110/60 mm Hg. Broad spectrum antibiotics (vancomycin
and pipercillin/tazobactam) were begun and the patient was
admitted to a telemetry floor. Initial studies included an
abdominal ultrasound which showed 2 hypoechoic masses in
the left lobe of the liver without intra- or extrahepatic ductal
dilatation noted. A non-contrast CT of the abdomen and pelvis
demonstrated innumerable lymph nodes scattered diffusely
throughout the mesentery and retroperitoneum measuring up
to 1.5 cm, likely related to the history of HIV infection. A renal
ultrasound showed normal sized kidneys, and no hydronephrosis. The nephrology service was consulted and the working
diagnosis at the time was renal failure secondary to tenofivir.

The tenofivir was discontinued and his abdominal pain workup
was continued.
The hospital course was notable for diarrhea, progressive lethargy,
fevers up to 104° F, worsening abdominal pain, continued rise
in serum creatinine to 5.1 mg/dL, and decreased urine output
to 200 cc’s over 24 hours. On hospital day 3, the patient was
transferred to the intensive care unit after an arterial blood gas
demonstrated a profound metabolic acidosis characterized by
a pH 7.15. A repeat non- contrast CT of abdomen and pelvis
now revealed diffuse, marked small bowel and large bowel wall
thickening with two focal segments suggestive of small bowel
intussusceptions without bowel obstruction.
The patient’s abnormal though non-specific intra-abdominal
findings in the setting of worsening acidosis and elevated
lactate levels prompted an exploratory laparotomy. Seven areas
of easily reducible intussusceptions were discovered. In fact,
innumerable mesenteric lymph nodes were found, believed to
act as lead points for the pathogenesis of these intussusceptions.
Fortunately, the bowel was still viable avoiding the need for
resection.
Post-op, the patient continued to be oliguric with severe
electrolyte imbalances (Urate 27.5, K 6.2 mEq/L, Ca2+ 3.0 mEq/
L, PO43- 17.4 mEq/L, LDH 1154 mEq/L). Spontaneous tumor
lysis syndrome was diagnosed and the patient was begun on
emergent hemodialysis. Intra-operatively obtained mesenteric
lymph nodes demonstrated atypical lymphoid cells with a high
mitotic rate that focally demonstrate a “starry-sky” pattern
consistent with a diagnosis of Burkitt lymphoma. Due to the
patient’s poor functional & physiologic status, it was decided
that he was a poor candidate for chemotherapy. The patient
elected no other therapies and elected for hospice care.

Discussion

Burkitt lymphoma is a rare disorder comprising less than 1% of
non Hodgkin B cell lymphomas. First described by Dr. Dennis
Burkitt in Uganda in 1958, it is an aggressive lymphoma frequently
presenting in extranodal sites, or as a leukemia, characterized by
monomorphic medium sized cells with a basophilic cytoplasm
and very high proliferation rate. It is classified by three major
types: endemic, sporadic, and immunodeficient.1,2
The endemic form is most common in Africa and New Guinea,
where is it the most common childhood neoplasm. The endemic
form typically affects facial bones in children (mean age 4-7)
and is associated with EBV more than 95% of the time. The
sporadic form occurs most commonly in developed countries
and a mean age of onset of 30. The sporadic form arises from
lymphoid tissue in the gut and respiratory tract with most cases
being extranodal and jaw involvement less than 30% of the time.
The immunodeficient form is associated with HIV infection and
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most commonly affects the lymph nodes and bone marrow.
Paradoxically, these patients typically have a high CD4 count
with few opportunistic infections.
The clinical presentation is varied and nonspecific, but
frequently involves the abdomen (i.e. pain, ascites). Patients
may also present with classic B symptoms of fevers, night
sweats, and weight loss. The diagnosis is confirmed with lymph
node biopsy, bone marrow biopsy, and lumbar puncture (the
last two necessary for deciding on treatment options).
The biology of the disease involved chromosomal translocation
and dysregulation of the c-myc gene, which controls cellular
proliferation.1 Tumor cells express a high level of the ki 67 protein
indicating high levels of mitotic activity. On pathology, sheets of
B cells are seen with frequent mitotic figures classically giving
the tumor cells a “starry sky” appearance. It is important to
differentiate between Burkitt and diffuse large B cell lymphoma
(which can sometimes have a similar pathologic appearance)
because the former is a more aggressive type of lymphoma
requiring intrathecal chemotherapy. Recently, molecular gene
signatures have been used to aid in this differentiation.
Typically, the Ann Arbor system is used in staging lymphomas;
however, Burkitt lymphoma does not lend itself well to the
staging system due to its extremely aggressive course. Due to the
nature of the tumor, chemotherapy needs to be initiated as soon
as possible, preferably within 48 hours of diagnosis. A standard
regimen includes cyclophosphamide, vincristine, doxorubicin,
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and high dose methotrexate and intrathecal therapy with
alternating ifosfamide, etoposide, and high dose cytarabine.
In one study, this regimen showed a 92% two year event free
survival in children and adults.3 The significant side effects
experienced were neurotoxicity, bone marrow suppression,
severe mucositis, and tumor lysis syndrome. Another study
showed that rituximab, a CD20 monoclonal antibody, further
increased two year event free survival (80-88%) when added to
the standard regimen. Studies are now under way with other
monoclonal antibodies and other biologic agents. There is no
clear role for bone marrow transplantation in the treatment of
the disease.
Once entertained, the diagnosis of Burkitt lymphoma should be
promptly confirmed with prompt initiation of chemotherapy to
combat the aggressive nature of this specific type of lymphoma.
New monocloncal antibody agents currently offer new survival
benefits not previously seen before.
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Case Reports

Spiderbite
Ayana Cannon, MD

Introduction

In North America alone, there are more than 3,000 species of
spiders. While most are harmless, several species including
the Latrodectus (black widow), Atrax (funnel-web), and the
Loxosceles (brown recluse) have been known to inflict varying
degrees of injury to humans. While an overwhelming majority
of spider bites may go unnoticed, others result in local skin
reactions, necrotic cutaneous lesions, or a severe syndrome
associated with hemolysis and death.

demonstrated two indurated 2.5 x 1 cm erythematous nodules
on his right medial forearm that were warm and tender to
palpation. The left forearm revealed 1 similar appearing nodule
with a 0.5 cm crusted central lesion. Serum laboratory tests
revealed an elevated erythrocyte sedimentation rate 33 mm/hr
and C-reactive protein 4.20 mg/dl. Compete blood count and
metabolic panel were within normal limits.

While proper identification of spider bites is paramount to
the prevention of rare, life-threatening systemic reactions,
their misdiagnosis can be equally hazardous. According to
the literature, Loxosceles reclusa bites are more frequently
being mistaken for community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA) infections, due to the
similarity of their classic lesion appearances. With the incidence
of CA-MRSA infections increasing, it is vital for members of the
healthcare community to effectively differentiate these lesions
to prevent delays in proper care. Complications resulting from
improper treatment of both CA-MRSA infections and spider
bites may be devastating.

Case Report

A 41 year-old man presented to the emergency room with a
one-week history of multiple, painful bumps on his left and
right forearms, accompanied by fever and chills for two days.
One day prior to the onset of his symptoms, the patient reported
receiving a shipment of sheet metal from Chicago, Illinois at
the construction company where he is employed in New Jersey.
Upon opening the large cardboard boxes, he noticed 3 large, dark
brown, spiders scurrying amongst the parcel. Later that night,
after returning home, the patient recalls redness and swelling
bordering two bumps on his right arm and 1 bump on his left
arm. The next morning he presented to an outside hospital
emergency department (ED) after awakening to sharp pains in
both of his arms. He was evaluated and discharged home with
oral trimethoprim/sulfamethaxazole to treat possible MRSA
cellulites. The next day, he noticed 2 additional spiders associated
with the materials shipped from Illinois, and captured one in a
bottle. According to the patient, this spider appeared to be the
same as those which he initially observed. The patient continued
his antibiotics, but noticed increasing pain and swelling around
the lesions on his arms with development of fever 100o F and
chills. He again reported to the ED with arachnoid in tow.
He had prior medical history of hyperlipidemia, no previous
surgical history, reported occasional alcohol use, but denied
tobacco and illicit drug use.
Vitals revealed a febrile temperature 101.5o F, mild hypertension
145/87 mm Hg, heart rate regular at 95 bpm, and normal
oxygen saturation without respiratory distress. Pysical exam

Figure 1. The patient was diagnosed with spider bite, presumptively
of the brown recluse type. He was discharged with a one week
course of Dapsone 50 mg, to be taken once daily. Within 48 hours,
wound cultures obtained from the patient upon presentation
grew methicillin-resistant staphylococcus aureus. The patient was
contacted and instructed to return to the outpatient clinic for
incision, drainage, and subsequent antibiotic treatment.

Discussion

In recent years, it has been reported that CA-MRSA has become
the most frequent cause of skin and soft tissue infections (SSTI’s)
presenting to ED’s in the United States.2,5 One study, carried
out at 11 geographically diverse institutions across the U.S.
in August 2004 showed that 99% of SSTI MRSA isolates were
characteristic of CA-MRSA.2 Studies published this year further
suggest that the incidence of MRSA infections may be higher
than previously believed with rates in 2005 approaching 32%
across 9 distinct U.S. communities.5,6 Among these infections,
researchers also found 15.7-22.2% of the isolates to be USA300
pulsed-field type, a characteristic historically associated with
CA-MRSA strains.5 Infection with such a pathogen can lead
to serious systemic complications such as bacteremia, septic
shock, and serious metastatic infections including endocarditis,
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pneumonia, osteomyelitis, and arthritis. Skin lesions due to
MRSA classically present as a furunculosis with an area of
inflammation around a darker purpuric center with overlying
dermonecrosis that is raised from the surrounding skin.7 The
differential diagnosis of such wounds includes Staphylococcal or
Streptococcal infection, cutaneous anthrax, and Lyme disease,
among others.8,9 Although CA-MRSA outbreaks have shown a
predilection for certain groups in the past, including prisoners,
men who have sex with men, IV drug users, military recruits,
and athletes, current data support the notion that CA-MRSA
strains are widespread among varying demographic populations
and associated with most SSTI’s presenting to the ED.
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Case Reports

Man with Malaria in Delaware
Benjamin Ngo, MD

Case Presentation

A 37-year-old African American male presented to the hospital
complaining of high fevers over the past two weeks associated
with severe posterior headache. He described having had a very
poor appetite recently, but denied any cough, abdominal pain,
diarrhea, or urinary symptoms. He did not recall sustaining
any head trauma. He did relate, however, that he had recently
returned from a three-month trip to Kenya ~1 month prior to
this presentation. He had no past medical history and was not
on any medications. He did not use IV drugs. Physical exam
confirmed a fever of 102.1o F though normotensive 110/82 mm
Hg and a resting heart rate 110 bpm. The complete physical
exam including cardiopulmonary, abdominal, and neurological
examination was normal. Laboratory analysis was unrevealing.
A head CT performed prior to the lumbar puncture also failed
to reveal any abnormalities. However, given the patient’s recent
travel history, the team empirically began him on antimalarial
treatment against P. falciparum (quinine sulfate 10 mg/kg every
eight hours and doxycycline 100mg po bid) while awaiting
confirmatory histologic diagnosis. The next day malaria was
confirmed when the results of the thick and thin smear were
positive for plasmodium with a viral level greater than 1%.
During his hospitalization he was noted to have recurrent fevers
occurring almost every other day. His clinical status remained
stable without any alterations of his laboratory data. He was
discharged to complete his course of oral medications.

Discussion

~300,000 to 500,000 new cases of malaria occur worldwide with
700,000 to 2.7 million deaths estimated worldwide. ~30,000
travelers from industrialized nations countries reportedly
contract malaria. Infection occurs through the transmission of
an infected Anopheles mosquito. Human malaria is caused by
four species of Plasmodia: P. falciparum, P. vivax, P. ovale, and
P. malariae. Each of the four species causes clinical disease by
resulting ultimately in hemolysis. P. falciparum has the ability
to invade red blood cells of all ages and it is associated with
the highest risk and rate of morbidity and mortality. Relapsing
fevers remain the clinical hallmark of malaria. Anemia,
thrombocytopenia, splenomegaly, hepatomegaly and jaundice
can develop, and splenic rupture can occasionally occur as well.
Altered consciousness, oliguira, hypoglycemia, and organ failure
are characteristics of severe P. falciparum infection.

serologic markers analysis. Thick and thin blood smears should
be examined at least every 12 hours to monitor the efficacy
of therapy until the parasitemia is below 1 %. Smears should
also be obtained at 3, 7, and 28 days to rule out recurrence or
incomplete clearance of parasitemia.
There are several medications available for the treatment of
malaria including quinoline derivatives, antifolates, artemisinin
derivatives, and antimicrobials. P. ovale and P. malariae
are universally sensitive to chloroquine. Several strains of
chloroquine-resistent P. vivax have been reported. The Centers
for Disease Control (CDC) recommend treatment of chloroquine
sensitive species of malaria with chloroquine followed by a
course of primaquine. Resistant P. vivax can be treated with
mefloquine or quinine sulfate plus doxycycline. Clinically, it is
very important that one distinguish between P. falciparum and
the other species of malaria, as P. falciparum is largely resistant
to chloroquine and this discernment will ultimately affect the
final drug cocktail prescribed. Failure to identify P. falciparum
could otherwise result in inadequate and delayed treatment with
the wrong medications. Fortunately, many treatment regimens
exist for the treatment of P. falciparum. The most commonly
recommend regimen is quinine sulfate with pyrimethaminesulfadoxine or doxycycline.
When advising patients on foreign travel, physicians should be
aware of resistance patterns of malaria based upon geographic
locale. This will tailor the choice of malarial prophylaxis unique
to the area. Prevention is paramount for travelers to endemic
areas and many resources through the CDC exist to provide
education to both clinicians and patients on anti-malarial
drugs.
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The diagnosis should be suspected in patients with recurrent
fevers that travel to endemic areas. The gold standard of
diagnosis is through examination of thick and thin smears with
light microscopy. Parasite levels are measurable and levels can
correlate with both type of species as well as portend overall
morbidity. Microscopy is regularly employed to assess a
patient’s response to treatment. Other diagnostic tests available
include antigen detection, fluorescent microscopy, PCR and
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Poem

WHAT’S UNDOCUMENTED
There’s a calm stillness
To the sick at night—
The sound of quiet healing, I hope,
But inevitably, a few cannot be healed.
Some patients walk that journey slowly, with
Humble shoulders slouched, weathered eyes closed,
Faltering against heavy feet.
Others stand and then seem to fall,
Out of nowhere, out of nothing,
Suddenly without breath, or pulse, or chance.
It can seem futile, our work,
At those moments, or sometimes tragic.
We don’t know the person being saved as a person well—
Their stories, their triumphs, their beginning—
We see only their scars, their end.
We then write a story in medical prose
That has its own inevitable circle—
A downward tailspin of vital signs, recorded in jargon,
Meant to document the loss of a life.
Death and dying as a sterile procedure,
That we all know is contaminated
By private prayers and irrational hope,
Questions about mortality and afterlife,
Suppressed emotions and subjectivity.
We leave out details, of course, of the heaviness,
Or sometimes the supreme lightness
That is somehow left—
Pervasive, tense, uncertain—
Undocumented and unspoken, but captured within.

Tamara Solitro, MD
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